AU4046489A – Post-transfusion, non-a, non-b hepatitis virus and antigens
– Google Patents
AU4046489A – Post-transfusion, non-a, non-b hepatitis virus and antigens
– Google Patents
Post-transfusion, non-a, non-b hepatitis virus and antigens
Info
Publication number
AU4046489A
AU4046489A
AU40464/89A
AU4046489A
AU4046489A
AU 4046489 A
AU4046489 A
AU 4046489A
AU 40464/89 A
AU40464/89 A
AU 40464/89A
AU 4046489 A
AU4046489 A
AU 4046489A
AU 4046489 A
AU4046489 A
AU 4046489A
Authority
AU
Australia
Prior art keywords
nanb
virus
sequence
antibodies
viral
Prior art date
1988-07-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU40464/89A
Inventor
Daniel W. Bradley
Kirk E. Fry
Linda Rabin
Gregory R. Reyes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Genelabs Inc
Original Assignee
Genelabs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1988-07-06
Filing date
1989-06-28
Publication date
1990-02-05
1989-06-28
Application filed by Genelabs Inc
filed
Critical
Genelabs Inc
1990-02-05
Publication of AU4046489A
publication
Critical
patent/AU4046489A/en
Status
Abandoned
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
241000700605
Viruses
Species
0.000
title
claims
description
133
239000000427
antigen
Substances
0.000
title
claims
description
77
102000036639
antigens
Human genes
0.000
title
claims
description
77
108091007433
antigens
Proteins
0.000
title
claims
description
77
208000006454
hepatitis
Diseases
0.000
title
claims
description
36
231100000283
hepatitis
Toxicity
0.000
title
claims
description
36
239000002245
particle
Substances
0.000
claims
description
103
238000000034
method
Methods
0.000
claims
description
66
108090000623
proteins and genes
Proteins
0.000
claims
description
59
210000004027
cell
Anatomy
0.000
claims
description
48
102000004169
proteins and genes
Human genes
0.000
claims
description
46
230000003612
virological effect
Effects
0.000
claims
description
39
208000015181
infectious disease
Diseases
0.000
claims
description
33
239000000523
sample
Substances
0.000
claims
description
32
210000002966
serum
Anatomy
0.000
claims
description
27
239000002773
nucleotide
Substances
0.000
claims
description
22
125000003729
nucleotide group
Chemical group
0.000
claims
description
22
241001465754
Metazoa
Species
0.000
claims
description
18
239000000463
material
Substances
0.000
claims
description
17
229960005486
vaccine
Drugs
0.000
claims
description
17
108091028043
Nucleic acid sequence
Proteins
0.000
claims
description
15
210000004754
hybrid cell
Anatomy
0.000
claims
description
15
239000003795
chemical substances by application
Substances
0.000
claims
description
14
239000000203
mixture
Substances
0.000
claims
description
13
239000012491
analyte
Substances
0.000
claims
description
12
230000003302
anti-idiotype
Effects
0.000
claims
description
10
239000003443
antiviral agent
Substances
0.000
claims
description
10
210000004408
hybridoma
Anatomy
0.000
claims
description
10
238000004519
manufacturing process
Methods
0.000
claims
description
10
230000002458
infectious effect
Effects
0.000
claims
description
9
238000002360
preparation method
Methods
0.000
claims
description
9
241000282579
Pan
Species
0.000
claims
description
8
230000027455
binding
Effects
0.000
claims
description
7
239000012472
biological sample
Substances
0.000
claims
description
7
239000013598
vector
Substances
0.000
claims
description
7
230000015572
biosynthetic process
Effects
0.000
claims
description
6
230000002163
immunogen
Effects
0.000
claims
description
6
230000000295
complement effect
Effects
0.000
claims
description
5
239000003814
drug
Substances
0.000
claims
description
5
230000001939
inductive effect
Effects
0.000
claims
description
5
108091033319
polynucleotide
Proteins
0.000
claims
description
5
102000040430
polynucleotide
Human genes
0.000
claims
description
5
239000002157
polynucleotide
Substances
0.000
claims
description
5
238000003786
synthesis reaction
Methods
0.000
claims
description
5
241000282412
Homo
Species
0.000
claims
description
4
229940079593
drug
Drugs
0.000
claims
description
4
210000003494
hepatocyte
Anatomy
0.000
claims
description
4
230000003053
immunization
Effects
0.000
claims
description
4
241000894006
Bacteria
Species
0.000
claims
description
3
206010019799
Hepatitis viral
Diseases
0.000
claims
description
3
230000002238
attenuated effect
Effects
0.000
claims
description
3
239000000356
contaminant
Substances
0.000
claims
description
3
238000001514
detection method
Methods
0.000
claims
description
3
230000002708
enhancing effect
Effects
0.000
claims
description
3
201000001862
viral hepatitis
Diseases
0.000
claims
description
3
230000001902
propagating effect
Effects
0.000
claims
description
2
230000000890
antigenic effect
Effects
0.000
claims
3
239000003550
marker
Substances
0.000
claims
1
230000010076
replication
Effects
0.000
claims
1
108090000765
processed proteins & peptides
Proteins
0.000
description
33
108020004635
Complementary DNA
Proteins
0.000
description
29
108020004414
DNA
Proteins
0.000
description
27
238000010804
cDNA synthesis
Methods
0.000
description
27
239000002299
complementary DNA
Substances
0.000
description
27
239000012634
fragment
Substances
0.000
description
23
241000282577
Pan troglodytes
Species
0.000
description
22
235000018102
proteins
Nutrition
0.000
description
22
150000001413
amino acids
Chemical group
0.000
description
21
235000001014
amino acid
Nutrition
0.000
description
18
229940024606
amino acid
Drugs
0.000
description
18
102000004196
processed proteins & peptides
Human genes
0.000
description
18
108091032973
(ribonucleotides)n+m
Proteins
0.000
description
16
238000003556
assay
Methods
0.000
description
14
238000009396
hybridization
Methods
0.000
description
13
238000010353
genetic engineering
Methods
0.000
description
10
239000013615
primer
Substances
0.000
description
9
230000002068
genetic effect
Effects
0.000
description
8
210000005229
liver cell
Anatomy
0.000
description
8
108020004705
Codon
Proteins
0.000
description
7
241000700721
Hepatitis B virus
Species
0.000
description
7
108020004511
Recombinant DNA
Proteins
0.000
description
7
238000002955
isolation
Methods
0.000
description
7
230000008569
process
Effects
0.000
description
7
235000002639
sodium chloride
Nutrition
0.000
description
7
210000004185
liver
Anatomy
0.000
description
6
239000013612
plasmid
Substances
0.000
description
6
229920001184
polypeptide
Polymers
0.000
description
6
XLYOFNOQVPJJNP-UHFFFAOYSA-N
water
Substances
O
XLYOFNOQVPJJNP-UHFFFAOYSA-N
0.000
description
6
102000053602
DNA
Human genes
0.000
description
5
108091034117
Oligonucleotide
Proteins
0.000
description
5
JLCPHMBAVCMARE-UHFFFAOYSA-N
[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate
Polymers
Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O
JLCPHMBAVCMARE-UHFFFAOYSA-N
0.000
description
5
230000003321
amplification
Effects
0.000
description
5
238000004458
analytical method
Methods
0.000
description
5
210000004369
blood
Anatomy
0.000
description
5
239000008280
blood
Substances
0.000
description
5
239000000499
gel
Substances
0.000
description
5
230000001900
immune effect
Effects
0.000
description
5
238000010166
immunofluorescence
Methods
0.000
description
5
210000004698
lymphocyte
Anatomy
0.000
description
5
238000003199
nucleic acid amplification method
Methods
0.000
description
5
150000003839
salts
Chemical class
0.000
description
5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N
Ethanol
Chemical compound
CCO
LFQSCWFLJHTTHZ-UHFFFAOYSA-N
0.000
description
4
229930006000
Sucrose
Natural products
0.000
description
4
CZMRCDWAGMRECN-UGDNZRGBSA-N
Sucrose
Chemical compound
O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
CZMRCDWAGMRECN-UGDNZRGBSA-N
0.000
description
4
230000002155
anti-virotic effect
Effects
0.000
description
4
230000004071
biological effect
Effects
0.000
description
4
238000005119
centrifugation
Methods
0.000
description
4
230000008859
change
Effects
0.000
description
4
239000003153
chemical reaction reagent
Substances
0.000
description
4
238000011161
development
Methods
0.000
description
4
238000003745
diagnosis
Methods
0.000
description
4
MHMNJMPURVTYEJ-UHFFFAOYSA-N
fluorescein-5-isothiocyanate
Chemical compound
O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21
MHMNJMPURVTYEJ-UHFFFAOYSA-N
0.000
description
4
230000028993
immune response
Effects
0.000
description
4
238000003018
immunoassay
Methods
0.000
description
4
239000006166
lysate
Substances
0.000
description
4
244000005700
microbiome
Species
0.000
description
4
150000007523
nucleic acids
Chemical class
0.000
description
4
239000000047
product
Substances
0.000
description
4
239000000126
substance
Substances
0.000
description
4
239000005720
sucrose
Substances
0.000
description
4
238000012360
testing method
Methods
0.000
description
4
230000009385
viral infection
Effects
0.000
description
4
CSCPPACGZOOCGX-UHFFFAOYSA-N
Acetone
Chemical compound
CC(C)=O
CSCPPACGZOOCGX-UHFFFAOYSA-N
0.000
description
3
PEDCQBHIVMGVHV-UHFFFAOYSA-N
Glycerine
Chemical compound
OCC(O)CO
PEDCQBHIVMGVHV-UHFFFAOYSA-N
0.000
description
3
241000709721
Hepatovirus A
Species
0.000
description
3
108020005187
Oligonucleotide Probes
Proteins
0.000
description
3
102000007079
Peptide Fragments
Human genes
0.000
description
3
108010033276
Peptide Fragments
Proteins
0.000
description
3
FAPWRFPIFSIZLT-UHFFFAOYSA-M
Sodium chloride
Chemical compound
[Na+].[Cl-]
FAPWRFPIFSIZLT-UHFFFAOYSA-M
0.000
description
3
DBMJMQXJHONAFJ-UHFFFAOYSA-M
Sodium laurylsulphate
Chemical compound
[Na+].CCCCCCCCCCCCOS([O-])(=O)=O
DBMJMQXJHONAFJ-UHFFFAOYSA-M
0.000
description
3
108010067390
Viral Proteins
Proteins
0.000
description
3
208000036142
Viral infection
Diseases
0.000
description
3
230000001154
acute effect
Effects
0.000
description
3
230000002411
adverse
Effects
0.000
description
3
238000001042
affinity chromatography
Methods
0.000
description
3
239000000872
buffer
Substances
0.000
description
3
238000004113
cell culture
Methods
0.000
description
3
238000010367
cloning
Methods
0.000
description
3
238000011109
contamination
Methods
0.000
description
3
239000003085
diluting agent
Substances
0.000
description
3
239000012153
distilled water
Substances
0.000
description
3
230000000694
effects
Effects
0.000
description
3
239000013604
expression vector
Substances
0.000
description
3
238000005194
fractionation
Methods
0.000
description
3
230000004927
fusion
Effects
0.000
description
3
239000001963
growth medium
Substances
0.000
description
3
238000002649
immunization
Methods
0.000
description
3
238000000338
in vitro
Methods
0.000
description
3
230000006698
induction
Effects
0.000
description
3
239000002054
inoculum
Substances
0.000
description
3
102000039446
nucleic acids
Human genes
0.000
description
3
108020004707
nucleic acids
Proteins
0.000
description
3
239000002751
oligonucleotide probe
Substances
0.000
description
3
230000000644
propagated effect
Effects
0.000
description
3
238000012216
screening
Methods
0.000
description
3
229940083575
sodium dodecyl sulfate
Drugs
0.000
description
3
235000019333
sodium laurylsulphate
Nutrition
0.000
description
3
239000000243
solution
Substances
0.000
description
3
241000894007
species
Species
0.000
description
3
238000010561
standard procedure
Methods
0.000
description
3
239000006228
supernatant
Substances
0.000
description
3
230000001225
therapeutic effect
Effects
0.000
description
3
238000002255
vaccination
Methods
0.000
description
3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N
(+)-Biotin
Chemical compound
N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21
YBJHBAHKTGYVGT-ZKWXMUAHSA-N
0.000
description
2
102100036475
Alanine aminotransferase 1
Human genes
0.000
description
2
108010082126
Alanine transaminase
Proteins
0.000
description
2
241000283707
Capra
Species
0.000
description
2
108091033380
Coding strand
Proteins
0.000
description
2
108700039691
Genetic Promoter Regions
Proteins
0.000
description
2
241000288105
Grus
Species
0.000
description
2
241000701044
Human gammaherpesvirus 4
Species
0.000
description
2
239000000020
Nitrocellulose
Substances
0.000
description
2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N
Phenol
Chemical compound
OC1=CC=CC=C1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N
0.000
description
2
MTCFGRXMJLQNBG-UHFFFAOYSA-N
Serine
Natural products
OCC(N)C(O)=O
MTCFGRXMJLQNBG-UHFFFAOYSA-N
0.000
description
2
108020000999
Viral RNA
Proteins
0.000
description
2
230000002378
acidificating effect
Effects
0.000
description
2
BFNBIHQBYMNNAN-UHFFFAOYSA-N
ammonium sulfate
Chemical compound
N.N.OS(O)(=O)=O
BFNBIHQBYMNNAN-UHFFFAOYSA-N
0.000
description
2
125000003118
aryl group
Chemical group
0.000
description
2
239000002585
base
Substances
0.000
description
2
239000011324
bead
Substances
0.000
description
2
150000001732
carboxylic acid derivatives
Chemical class
0.000
description
2
238000006243
chemical reaction
Methods
0.000
description
2
238000004587
chromatography analysis
Methods
0.000
description
2
230000002950
deficient
Effects
0.000
description
2
238000010790
dilution
Methods
0.000
description
2
239000012895
dilution
Substances
0.000
description
2
108010074605
gamma-Globulins
Proteins
0.000
description
2
208000002672
hepatitis B
Diseases
0.000
description
2
238000011534
incubation
Methods
0.000
description
2
239000007924
injection
Substances
0.000
description
2
238000002347
injection
Methods
0.000
description
2
235000006109
methionine
Nutrition
0.000
description
2
238000012986
modification
Methods
0.000
description
2
230000004048
modification
Effects
0.000
description
2
229920001220
nitrocellulos
Polymers
0.000
description
2
239000008188
pellet
Substances
0.000
description
2
125000002924
primary amino group
Chemical group
[H]N([H])*
0.000
description
2
238000000746
purification
Methods
0.000
description
2
230000000717
retained effect
Effects
0.000
description
2
239000011780
sodium chloride
Substances
0.000
description
2
239000007787
solid
Substances
0.000
description
2
238000010257
thawing
Methods
0.000
description
2
210000001519
tissue
Anatomy
0.000
description
2
238000010396
two-hybrid screening
Methods
0.000
description
2
238000005406
washing
Methods
0.000
description
2
MTCFGRXMJLQNBG-REOHCLBHSA-N
(2S)-2-Amino-3-hydroxypropansäure
Chemical compound
OC[C@H](N)C(O)=O
MTCFGRXMJLQNBG-REOHCLBHSA-N
0.000
description
1
102000040650
(ribonucleotides)n+m
Human genes
0.000
description
1
QKNYBSVHEMOAJP-UHFFFAOYSA-N
2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride
Chemical compound
Cl.OCC(N)(CO)CO
QKNYBSVHEMOAJP-UHFFFAOYSA-N
0.000
description
1
BFSVOASYOCHEOV-UHFFFAOYSA-N
2-diethylaminoethanol
Chemical compound
CCN(CC)CCO
BFSVOASYOCHEOV-UHFFFAOYSA-N
0.000
description
1
UZOVYGYOLBIAJR-UHFFFAOYSA-N
4-isocyanato-4′-methyldiphenylmethane
Chemical compound
C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1
UZOVYGYOLBIAJR-UHFFFAOYSA-N
0.000
description
1
HRPVXLWXLXDGHG-UHFFFAOYSA-N
Acrylamide
Chemical compound
NC(=O)C=C
HRPVXLWXLXDGHG-UHFFFAOYSA-N
0.000
description
1
108091003079
Bovine Serum Albumin
Proteins
0.000
description
1
CURLTUGMZLYLDI-UHFFFAOYSA-N
Carbon dioxide
Chemical compound
O=C=O
CURLTUGMZLYLDI-UHFFFAOYSA-N
0.000
description
1
241000543381
Cliftonia monophylla
Species
0.000
description
1
239000003155
DNA primer
Substances
0.000
description
1
239000003298
DNA probe
Substances
0.000
description
1
230000006820
DNA synthesis
Effects
0.000
description
1
102000016928
DNA-directed DNA polymerase
Human genes
0.000
description
1
108010014303
DNA-directed DNA polymerase
Proteins
0.000
description
1
241001533413
Deltavirus
Species
0.000
description
1
229920002307
Dextran
Polymers
0.000
description
1
KCXVZYZYPLLWCC-UHFFFAOYSA-N
EDTA
Chemical compound
OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O
KCXVZYZYPLLWCC-UHFFFAOYSA-N
0.000
description
1
108090000790
Enzymes
Proteins
0.000
description
1
102000004190
Enzymes
Human genes
0.000
description
1
241000711549
Hepacivirus C
Species
0.000
description
1
208000005176
Hepatitis C
Diseases
0.000
description
1
241000724709
Hepatitis delta virus
Species
0.000
description
1
108090000144
Human Proteins
Proteins
0.000
description
1
102000003839
Human Proteins
Human genes
0.000
description
1
108060003951
Immunoglobulin
Proteins
0.000
description
1
QNAYBMKLOCPYGJ-REOHCLBHSA-N
L-alanine
Chemical compound
C[C@H](N)C(O)=O
QNAYBMKLOCPYGJ-REOHCLBHSA-N
0.000
description
1
CKLJMWTZIZZHCS-REOHCLBHSA-N
L-aspartic acid
Chemical compound
OC(=O)[C@@H](N)CC(O)=O
CKLJMWTZIZZHCS-REOHCLBHSA-N
0.000
description
1
WHUUTDBJXJRKMK-VKHMYHEASA-N
L-glutamic acid
Chemical compound
OC(=O)[C@@H](N)CCC(O)=O
WHUUTDBJXJRKMK-VKHMYHEASA-N
0.000
description
1
AGPKZVBTJJNPAG-WHFBIAKZSA-N
L-isoleucine
Chemical compound
CC[C@H](C)[C@H](N)C(O)=O
AGPKZVBTJJNPAG-WHFBIAKZSA-N
0.000
description
1
ROHFNLRQFUQHCH-YFKPBYRVSA-N
L-leucine
Chemical compound
CC(C)C[C@H](N)C(O)=O
ROHFNLRQFUQHCH-YFKPBYRVSA-N
0.000
description
1
FFEARJCKVFRZRR-BYPYZUCNSA-N
L-methionine
Chemical compound
CSCC[C@H](N)C(O)=O
FFEARJCKVFRZRR-BYPYZUCNSA-N
0.000
description
1
KZSNJWFQEVHDMF-BYPYZUCNSA-N
L-valine
Chemical compound
CC(C)[C@H](N)C(O)=O
KZSNJWFQEVHDMF-BYPYZUCNSA-N
0.000
description
1
ROHFNLRQFUQHCH-UHFFFAOYSA-N
Leucine
Natural products
CC(C)CC(N)C(O)=O
ROHFNLRQFUQHCH-UHFFFAOYSA-N
0.000
description
1
201000005505
Measles
Diseases
0.000
description
1
108700026244
Open Reading Frames
Proteins
0.000
description
1
101710160107
Outer membrane protein A
Proteins
0.000
description
1
239000002202
Polyethylene glycol
Substances
0.000
description
1
241000288906
Primates
Species
0.000
description
1
239000003391
RNA probe
Substances
0.000
description
1
206010037742
Rabies
Diseases
0.000
description
1
102000007056
Recombinant Fusion Proteins
Human genes
0.000
description
1
108010008281
Recombinant Fusion Proteins
Proteins
0.000
description
1
229920005654
Sephadex
Polymers
0.000
description
1
239000012507
Sephadex™
Substances
0.000
description
1
108020004682
Single-Stranded DNA
Proteins
0.000
description
1
238000002105
Southern blotting
Methods
0.000
description
1
AYFVYJQAPQTCCC-UHFFFAOYSA-N
Threonine
Natural products
CC(O)C(N)C(O)=O
AYFVYJQAPQTCCC-UHFFFAOYSA-N
0.000
description
1
239000004473
Threonine
Substances
0.000
description
1
KZSNJWFQEVHDMF-UHFFFAOYSA-N
Valine
Natural products
CC(C)C(N)C(O)=O
KZSNJWFQEVHDMF-UHFFFAOYSA-N
0.000
description
1
108010003533
Viral Envelope Proteins
Proteins
0.000
description
1
108700005077
Viral Genes
Proteins
0.000
description
1
238000010521
absorption reaction
Methods
0.000
description
1
239000002253
acid
Chemical class
0.000
description
1
230000009471
action
Effects
0.000
description
1
239000002671
adjuvant
Substances
0.000
description
1
239000011543
agarose gel
Substances
0.000
description
1
235000004279
alanine
Nutrition
0.000
description
1
239000003513
alkali
Substances
0.000
description
1
-1
alkaline earth
Substances
0.000
description
1
229910052921
ammonium sulfate
Inorganic materials
0.000
description
1
235000011130
ammonium sulphate
Nutrition
0.000
description
1
210000004102
animal cell
Anatomy
0.000
description
1
239000008346
aqueous phase
Substances
0.000
description
1
239000007864
aqueous solution
Substances
0.000
description
1
229940009098
aspartate
Drugs
0.000
description
1
238000000376
autoradiography
Methods
0.000
description
1
230000001580
bacterial effect
Effects
0.000
description
1
102000005936
beta-Galactosidase
Human genes
0.000
description
1
108010005774
beta-Galactosidase
Proteins
0.000
description
1
239000011230
binding agent
Substances
0.000
description
1
230000005540
biological transmission
Effects
0.000
description
1
229960002685
biotin
Drugs
0.000
description
1
235000020958
biotin
Nutrition
0.000
description
1
239000011616
biotin
Substances
0.000
description
1
239000012503
blood component
Substances
0.000
description
1
230000036770
blood supply
Effects
0.000
description
1
210000001124
body fluid
Anatomy
0.000
description
1
230000037396
body weight
Effects
0.000
description
1
229940098773
bovine serum albumin
Drugs
0.000
description
1
239000007975
buffered saline
Substances
0.000
description
1
AIYUHDOJVYHVIT-UHFFFAOYSA-M
caesium chloride
Chemical compound
[Cl-].[Cs+]
AIYUHDOJVYHVIT-UHFFFAOYSA-M
0.000
description
1
210000000234
capsid
Anatomy
0.000
description
1
150000001720
carbohydrates
Chemical class
0.000
description
1
235000011089
carbon dioxide
Nutrition
0.000
description
1
239000000969
carrier
Substances
0.000
description
1
150000001768
cations
Chemical class
0.000
description
1
239000006285
cell suspension
Substances
0.000
description
1
230000001413
cellular effect
Effects
0.000
description
1
230000001684
chronic effect
Effects
0.000
description
1
238000003776
cleavage reaction
Methods
0.000
description
1
239000013599
cloning vector
Substances
0.000
description
1
238000010961
commercial manufacture process
Methods
0.000
description
1
239000000306
component
Substances
0.000
description
1
235000009508
confectionery
Nutrition
0.000
description
1
239000000470
constituent
Substances
0.000
description
1
238000010276
construction
Methods
0.000
description
1
230000008878
coupling
Effects
0.000
description
1
238000010168
coupling process
Methods
0.000
description
1
238000005859
coupling reaction
Methods
0.000
description
1
238000012258
culturing
Methods
0.000
description
1
235000018417
cysteine
Nutrition
0.000
description
1
XUJNEKJLAYXESH-UHFFFAOYSA-N
cysteine
Natural products
SCC(N)C(O)=O
XUJNEKJLAYXESH-UHFFFAOYSA-N
0.000
description
1
230000009089
cytolysis
Effects
0.000
description
1
230000003247
decreasing effect
Effects
0.000
description
1
238000004925
denaturation
Methods
0.000
description
1
230000036425
denaturation
Effects
0.000
description
1
238000009792
diffusion process
Methods
0.000
description
1
201000010099
disease
Diseases
0.000
description
1
208000037265
diseases, disorders, signs and symptoms
Diseases
0.000
description
1
210000003743
erythrocyte
Anatomy
0.000
description
1
239000002360
explosive
Substances
0.000
description
1
238000001914
filtration
Methods
0.000
description
1
230000003311
flocculating effect
Effects
0.000
description
1
239000012530
fluid
Substances
0.000
description
1
230000008014
freezing
Effects
0.000
description
1
238000007710
freezing
Methods
0.000
description
1
102000037865
fusion proteins
Human genes
0.000
description
1
108020001507
fusion proteins
Proteins
0.000
description
1
238000001502
gel electrophoresis
Methods
0.000
description
1
238000005227
gel permeation chromatography
Methods
0.000
description
1
238000007429
general method
Methods
0.000
description
1
229930195712
glutamate
Natural products
0.000
description
1
HNDVDQJCIGZPNO-UHFFFAOYSA-N
histidine
Natural products
OC(=O)C(N)CC1=CN=CN1
HNDVDQJCIGZPNO-UHFFFAOYSA-N
0.000
description
1
230000000899
immune system response
Effects
0.000
description
1
230000009851
immunogenic response
Effects
0.000
description
1
102000018358
immunoglobulin
Human genes
0.000
description
1
229940072221
immunoglobulins
Drugs
0.000
description
1
230000000977
initiatory effect
Effects
0.000
description
1
238000011081
inoculation
Methods
0.000
description
1
150000002500
ions
Chemical class
0.000
description
1
229960000310
isoleucine
Drugs
0.000
description
1
AGPKZVBTJJNPAG-UHFFFAOYSA-N
isoleucine
Natural products
CCC(C)C(N)C(O)=O
AGPKZVBTJJNPAG-UHFFFAOYSA-N
0.000
description
1
108010045069
keyhole-limpet hemocyanin
Proteins
0.000
description
1
239000004816
latex
Substances
0.000
description
1
229920000126
latex
Polymers
0.000
description
1
230000000670
limiting effect
Effects
0.000
description
1
238000012317
liver biopsy
Methods
0.000
description
1
238000000464
low-speed centrifugation
Methods
0.000
description
1
230000002934
lysing effect
Effects
0.000
description
1
210000002540
macrophage
Anatomy
0.000
description
1
239000011159
matrix material
Substances
0.000
description
1
239000002609
medium
Substances
0.000
description
1
239000012528
membrane
Substances
0.000
description
1
210000004779
membrane envelope
Anatomy
0.000
description
1
108020004999
messenger RNA
Proteins
0.000
description
1
229910052751
metal
Inorganic materials
0.000
description
1
239000002184
metal
Substances
0.000
description
1
229930182817
methionine
Natural products
0.000
description
1
150000002742
methionines
Chemical class
0.000
description
1
108091005601
modified peptides
Proteins
0.000
description
1
238000010369
molecular cloning
Methods
0.000
description
1
238000012544
monitoring process
Methods
0.000
description
1
230000009871
nonspecific binding
Effects
0.000
description
1
235000015097
nutrients
Nutrition
0.000
description
1
230000001575
pathological effect
Effects
0.000
description
1
230000007170
pathology
Effects
0.000
description
1
210000005259
peripheral blood
Anatomy
0.000
description
1
239000011886
peripheral blood
Substances
0.000
description
1
239000012071
phase
Substances
0.000
description
1
239000013600
plasmid vector
Substances
0.000
description
1
229920001223
polyethylene glycol
Polymers
0.000
description
1
238000003752
polymerase chain reaction
Methods
0.000
description
1
239000011148
porous material
Substances
0.000
description
1
238000012809
post-inoculation
Methods
0.000
description
1
230000001376
precipitating effect
Effects
0.000
description
1
239000002243
precursor
Substances
0.000
description
1
239000002987
primer (paints)
Substances
0.000
description
1
238000011321
prophylaxis
Methods
0.000
description
1
201000005484
prostate carcinoma in situ
Diseases
0.000
description
1
230000009257
reactivity
Effects
0.000
description
1
238000010188
recombinant method
Methods
0.000
description
1
238000011084
recovery
Methods
0.000
description
1
230000001105
regulatory effect
Effects
0.000
description
1
238000011160
research
Methods
0.000
description
1
108091008146
restriction endonucleases
Proteins
0.000
description
1
230000000979
retarding effect
Effects
0.000
description
1
230000002441
reversible effect
Effects
0.000
description
1
IOVGROKTTNBUGK-SJCJKPOMSA-N
ritodrine
Chemical compound
N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1
IOVGROKTTNBUGK-SJCJKPOMSA-N
0.000
description
1
230000007017
scission
Effects
0.000
description
1
238000000926
separation method
Methods
0.000
description
1
239000007974
sodium acetate buffer
Substances
0.000
description
1
239000007790
solid phase
Substances
0.000
description
1
239000002195
soluble material
Substances
0.000
description
1
239000002904
solvent
Substances
0.000
description
1
230000009870
specific binding
Effects
0.000
description
1
210000000952
spleen
Anatomy
0.000
description
1
210000004989
spleen cell
Anatomy
0.000
description
1
238000010911
splenectomy
Methods
0.000
description
1
239000007858
starting material
Substances
0.000
description
1
239000008174
sterile solution
Substances
0.000
description
1
238000007920
subcutaneous administration
Methods
0.000
description
1
238000006467
substitution reaction
Methods
0.000
description
1
230000009885
systemic effect
Effects
0.000
description
1
238000012546
transfer
Methods
0.000
description
1
230000009466
transformation
Effects
0.000
description
1
238000013519
translation
Methods
0.000
description
1
238000000108
ultra-filtration
Methods
0.000
description
1
238000011144
upstream manufacturing
Methods
0.000
description
1
239000004474
valine
Substances
0.000
description
1
230000007502
viral entry
Effects
0.000
description
1
239000011800
void material
Substances
0.000
description
1
239000011534
wash buffer
Substances
0.000
description
1
Classifications
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
C07K16/109—Hepatitis C virus; Hepatitis G virus
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
C12Q1/701—Specific hybridization probes
C12Q1/706—Specific hybridization probes for hepatitis
C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K38/00—Medicinal preparations containing peptides
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K39/00—Medicinal preparations containing antigens or antibodies
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
C12N2770/00011—Details
C12N2770/24011—Flaviviridae
C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
C12N2770/00011—Details
C12N2770/24011—Flaviviridae
C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Description
POST-TRANSFUSION, NON-A, NON-B HEPATITIS VIRUS AND ANTIGENS
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation in part of US Application Serial No. 350,570, filed May 11, 1989, which is a continuation in part of US Application Serial No. 334,701, filed April 6, 1989, which is a continuation in part of US Application Serial No.
228,334, filed August 4, 1988, which is a continuation in part of US Application Serial No. 215,728, filed July 6, 1988, which is a continuation in part of US Application Serial No. 846,757, filed April 1, 1986, which disclosures are hereby incorporated herein by reference.
INTRODUCTION
Technical Field
This invention relates to virus associated with post transfusion non-A, non-B (PT-NANB) hepatitis, to PT-NANB antigens produced by recombinant processes, and to products and processes associated with vaccination against, diagnosis of, and prophylaxis of PT-NANB hepatitis.
Background
Acute viral hepatitis is a systemic infection with predominant pathology affecting the liver. Five types of viral agents which cause hepatitis are known to exist: hepatitis A virus (HAV), hepatitis B virus (HBV), post transfusion (PT) and enteric transmission (ET), non-A, non-B (NANB) hepatitis agents, and the
HBV-associated delta virus. Specific viral agents have been associated with HAV, HBV, and delta virus. How¬ ever, despite numerous publications reporting agents associated with PT-NANB hepatitis, there does not appear to be any consensus that the etiologic agent has been identified. Harrison’s Principals of Internal Medicine, 11th edition (1987), reports that there are at least two different blood-borne NANB hepatitis agents, although the virus(es) or virus antigens are said not to have been identified definitively.
Routine screening of blood donors for anti-HBV antibody and HBV antigen (HBsAg) has decreased the incidence of hepatitis B after blood transfusion, but post-transfusion PT hepatitis due to infection with NANB hepatitis agents is still a significant problem because of the lack of an acceptable serologic screen¬ ing test to identify PT-NANB hepatitis agents. Identification of new viruses and the use of genetic information obtained from the viruses to produce recombinant proteins that are safe for use in vaccines and diagnostics are major goals in the development of. a safe blood supply.
Relevant Literature PT-NANB viruses and antigens have been re¬ ported. See for example, U.S. Patent Nos. 4,464,474, and 4,542,016. The PT-NANB virus has been reported to be a togavirus. See, for example, U.S. Patent No. 4,464,474. Genetic engineering of hepatitis viral genes, identified as hepatitis C virus, is reported in European Patent Application 88310922.5 (publication number 0 318 216 Al).
SUMMARY OF THE INVENTION
In accordance with the subject invention, isolates comprising virus particles associated with PT-
NANB hepatitis and genomic material derived therefrom, together with methods for their preparation and use, are provided. The virus particles are characterized as being obtainable from cells susceptible to NANB hepatitis infection in a host infected with NANB hepatitis; capable of inducing NANB hepatitis in a susceptible host; and capable of inducing expression of NANB virus specific antigens in cells susceptible to infection by the virus. The virus particles can be used as a source of genomic material for preparing polynucleotide probes for diagnosis, as well as antigens and vaccines for therapeutic and diagnostic applications. Propagation of the virus particles in vitro can be used to identify virus-specific cell- surface antigens, and as a source of such antigens. Attenuated or inactivated virus particles can be used as vaccines.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows a fragment of PT-NANB virus derived from clone #30. The top line represents the amino acid sequence which is encoded by the nucleotide sequence shown in the lower line. Figure 2 shows a fragment of PT-NANB virus derived from λgt-11 clone PT-2. Abbreviations are as for Figure 1.
Figure 3 shows a fragment of PT-NANB virus derived from λgt-11 clone PT-8. Abbreviations are as for Figure 1.
Figure 4 shows a fragment of PT-NANB virus derived from λgt-11 clone PT-19. Abbreviations are as for Figure 1.
Figure 5 shows a series of 7 fragments of PT- NANB virus genetic material. Only the cDNA sequences are shown in this Figure.
DESCRIPTION OF THE SPECIFIC EMBODIMENTS
The present invention provides unambiguously identified viral genetic material and a source of virus particles associated with post transfusion non-A, non-B (NANB) hepatitis. The virus particles may be obtained from samples suspected of containing virus particles, such as serum of infected humans and*other- anthropoid species, by fractionation of the samples baJse’d upon buoyuant density and from cells susceptible to infection with NANB virus, such as hepatocytes. The virus particle isolates may be used directly as a source of genomic material for preparing probes for diagnosis, antigens and vaccines for*-therapeutic and diagnostic purposes, or they may be propagated in a susceptible cell line such as a trioma comprising human hepatocytes. The infected cells may be used either as a source of virus particles or may be used’ for identi¬ fying NANB virus specific antibodies or antigens, and as a source of such antigens.
Viral particles can be obtained from an infected human or other infected source such as a chimpanzee, from plasma, or from other cells suscept¬ ible to infection by NANB virus, such as the hepato- cyte. To obtain viral genomic material, the biological sample can be centrifuged and viral RNA extracted from viral particles in the sample. Alternatively, a purified fraction comprising viral particles may be obtained by fractionation of the sample on a density gradient, such as a sucrose density gradient.
Fractions having a buoyant density of from about 1.07 to about 1.13 gm/cm , preferably 1.09 to 1.11 gm/cir are collected. Fractions comprising the virus particles can then be extracted and cDNA clones prepared from the viral RNA. The virus may be further characterized as having a genome comprising RNA sequences which may be reverse transcribed to obtain at
least one of the cDNA sequences shown in Figures 1-5. All of these sequences are derived from viral genetic material isolated from humans or chimpanzees infected with PT NANB. For example, the first five sequences shown in Figure 5 are derived from virus obtained from humans. These sequences are derived from different segments of the viral genome and appear to be unrelated. The last two sequences shown in Figure 5 are derived from virus obtained from infected chimpanzees. All of these sequences appear to be different from previously known NANB sequences, such as those disclosed in published European application 0 318 216 Al, which was mentioned above as identifying hepatitis C viral segments. Any sequence of nucleotides from the above sequences may be used as a probe or primer for detecting or regulating the viral nucleic acid. Such probes can be considerably shorter than the entire sequence but should be at least 16 nucleotides in length. Intermediate oligonucleotides from 20 to 500, especially 30 to 200, nucleotides in length provide particularly specific and rapid-acting probes. Longer oligonucleotides are also useful, up to the full length of a gene. Both RNA and DNA probes may be used. In addition, an at least 8, usually at least 12 amino acid sequence, conveniently at least a 20-amino acid sequence, may be employed as an epitopic site, an immunodominant sequence, a hapten or the like for the production of diagnostic reagents, vaccines, production of antibodies, isolation of antibodies from serum or the like. Usually, the isolated peptide will be fewer than about 125 amino acids, frequently fewer than about 100 amino acids. A phipathic sequences or sequences fulfilling the Rothbard algorithm may be used, as exemplified by G-V-V-Y-D-N-D-D, or E-P-V-N-P-K-D-P.
Sequences homologous with the viral sequences should hybridize and be detectable under the conditions
described for detecting/hybridizing RNA in Maniatis et_ al. , Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1982, p. 332. See also, pages 324-328 for DNA hybridization conditions, particularly paragraph 6, p. 325.
Since significant sequences of genetic material (as cDNA) have been fully identified, it is possible to produce a variety of DNA and RNA sequences based on-this natural sequence partially or entirely by synthetic chemistry, after which the sequences obtained can be inserted into any of the many available DNA vec¬ tors using known techniques of recombinant DNA technol¬ ogy. Thus the present invention can be carried out using reagents, plasmids, and microorganism which are freely available and in the public domain at the time of filing of this patent application.
For example, nucleotide sequences greater than 100 nucleotides in length can be readily synthesized on an Applied Biosystems Model 380A DNA Synthesizer as evidenced by commercial advertising of the same (e.g.. Genetic Engineering News, November/December 1984, p. 3). Such oligonucleotides can readily be spliced using, among others, the technique of preparing over¬ lapping complementary sequences (e.g., 1-100 of coding strand, 0-50 and 51-150 of complementary strand, 101-
200 of coding strand, etc.) followed by hybridizing and ligating the strands.
Furthermore, automated equipment is also available that makes direct synthesis of any of the peptides disclosed herein readily available. In the same issue of Genetic Engineering News mentioned above, a commercially available automated peptide synthesizer having a coupling efficiency exceeding 99% is adver¬ tised (page 34). Such equipment provides ready access to the peptides of the invention, either by direct syn¬ thesis or by synthesis of a series of fragments that can be coupled using other known techniques.
In addition to the specific polypeptide se¬ quences shown in Figures 1 to 5, peptide fragments based on these sequences and fragments representing minor variations thereof will have the biological activity of the various peptides. For example, fragments of the given peptide sequence that are capable of being recognized by immunoglobulins specific for NANB hepatitis can readily be prepared and screened. Peptide synthesizers can be used to prepare small polypeptide fragments (e.g., less than 100 amino acids) or techniques of genetic engineering can be used to prepare larger fragments. A simple screening procedure that will identify suitable polypeptide fragments consists of preparing monoclonal antibodies to an entire encoded antigen, attaching the antibodies to an affinity column, and capturing peptide fragments that are retained by the bound antibody. Polyclonal antisera can be used instead of monoclonal antibodies if desired. The suitability of this technique has been demonstrated experimentally.
The ability to prepare and select appropriate immunologically active fragments from a larger protein is well known in the art and is described in a number of publications, including patents. See, for example, U.S. Patent No. 4,629,783, which describes the prepar¬ ation of immunologically active fragments of viral proteins. One common variation is the preparation of a polypeptide of the invention in the form of a fused polypeptide. Such peptides are typically prepared by using the promoter region of a gene known to be ex¬ pressed in a host and inserting nucleotides that encode all or a major portion of the amino acid sequence of the invention into the genetic sequence for the host protein. Examples of such fused proteins include the β-galactosidase fused protein discussed below.
Another technique for preparing immunological¬ ly active peptide fragments is to synthesize a series
of amino acids of from 5-100 amino acids in length (or any intervening length, such as 10, 15, or any other multiple of 2, 3, or 5 in this range) and screen for immunological activity using an antiserum (or mono- clonal antibody) . The fragments are selected along the entire length of the peptide to optimize cross-reactiv¬ ity (e.g., a series of peptides 20 amino acids in length and comprising AA-L-AA2Q, AA5-AA25, AA***_Q-AA3Q, etc. ) . The selected fragment then corresponds to particularly useful corresponding nucleotide sequences that can be used to produce large amounts of the peptide by recombinant techniques, for use as described herein.
In addition, minor variations of the previous- ly mentioned peptides and DNA molecules are also con¬ templated as being equivalent to those peptides and DNA molecules that are set forth in more detail, as will be appreciated by those skilled in the art. For example, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, a cysteine with a serine or alanine, or a similar replacement of an amino acid with a structurally related amino acid (i.e., a conservative replacement) will not have a major effect on the biological activity of the resul¬ ting molecule, especially if the replacement does not involve an amino acid at a binding site or ‘other site of biologic activity. Whether a change results in a functioning peptide can readily be determined by direct analysis for function in an immunization or in a diag¬ nostic test that relies on immunogenic specificity. Examples of this process are described later in detail. Peptides in which more than one replacement has taken place can readily be tested in the same manner. Preferred peptides differ at no more t.ian 12, more preferably no more than 5, amino acids in any contiguous group of 20 amino acids. Standard conser-
vative groups of amino acids are shown in parenthesis using the one-letter amino acid code: nonpolar (A,V,L,I,P,M) ; aromatic (F,T,W); uncharged polar (G,S,T,C,N,Q) ; acidic (D,E); basic (K,R,H). The aroma- tic groups are sometimes considered to belong to the broader-defined nonpolar (F,W) or uncharged polar (T) groups.
Other DNA molecules that code for such pep¬ tides can readily be determined from the list of codons in Table 1 and are likewise contemplated as being equi¬ valent to the DNA sequences of Figures 1 to 5. Since there is a fixed relationship between DNA codons and amino acids in a peptide, any discussion in this appli¬ cation of a replacement or other change in a peptide is equally applicable to the corresponding DNA sequence or to the DNA molecule, recombinant vector, or transformed microorganism in which the sequence is located (and vice versa) .
TABLE 1
The Genetic Code1
1 Given the position of the bases in a codon, it is possible to find the corresponding amino acid. For example, the codon (5*)AUG(3′) on mRNA specifies methionine, whereas CAU specifies histidine. UUA, UAG, and UGA are termination signals. AUG is part of the initiation signal, and it codes for internal methionines as well.
In addition to the specific nucleotide sequences listed in Figures 1 to 5, DNA (or corresponding RNA) molecules of the invention can have additional nucleotides preceding or following those that are specifically listed. For example, poly A can be added to the 3’-terminus of the cDNA, a short (e.g., fewer than 20 nucleotides) sequence can be added to either terminus to provide a terminal sequence corre¬ sponding to a restriction endonuclease site, stop codons can follow the peptide sequence to terminate translation, and the like. Additionally, DNA molecules containing a promoter region or other control region upstream from the gene can be prepared. All DNA mole¬ cules containing the sequences of the invention will be useful for at least one purpose since all can minimally be fragmented to produce oligonucleotide probes and be used in the isolation or detection of PT NANB specific nucleic acid sequences from biological sources.
Peptides of the invention can be prepared for the first time as homogeneous preparations, either by direct synthesis or by using a cloned gene or a frag¬ ment thereof as described herein. By “homogeneous” is meant, when referring to a peptide or DNA sequence, that the primary molecular structure (i.e., the se- quence of amino acids or nucleotides) of substantially all molecules present in the composition under consi¬ deration is identical. The term “substantially” as used in the preceding sentence preferably means at least 95% by weight, more preferably at least 99% by weight, and most preferably at least 99.8% by weight.
The presence of fragments derived from entire molecules of the homogeneous peptide or DNA sequence, if present in no more than 5% by weight, preferably 1% by weight, and more preferably 0.2% by weight, is not to be consi- dered in determining homogeneity since the term “homo¬ geneous” relates to the presence of entire molecules (and fragments thereof) that have a single defined
structure as opposed to mixtures in which several mole¬ cules of similar molecular weight are present but which differ in their primary molecular structure.
The term “isolated” as used herein refers to pure peptide, DNA, or RNA separated from other pep¬ tides, DNAs, or RNAs, respectively, and being found in the presence of (if anything) only a solvent, buffer, ion or other component normally present in a biochemi¬ cal solution of the same. “Isolated” does not encom- pass either natural materials in their native state or natural materials that have been separated into compo¬ nents (e.g., in an acrylamide gel) but which have not been obtained either as pure substances or as solu¬ tions. The term “pure” as used herein preferably has the same numerical limits as “substantially” immediate¬ ly above. The phrase “replaced by” or “replacement” as used herein does not necessarily refer to any action that must take place but to the peptide that exists when an indicated “replacement” amino acid is present in the same position as the amino acid indicated to be present in a different formula.
Salts of any of the biological molecules de¬ scribed herein will naturally occur when such molecules are present in (or isolated from) aqueous solutions of various pHs. All salts of molecules having the indica¬ ted biological activity are considered to be within the scope of the present invention. Examples of salts that can occur with peptides include alkali, alkaline earth, and other metal salts of carboxylic acid residues, acid addition salts (e.g., HCl) of amino residues, and zw;itterions formed by reactions between carboxylic acid and amino residues within the same molecule.
The invention specifically contemplates each and every possible variation of polynucleotide that could be made by selecting combinations based on the possible codon choices listed in Figures 1 to 5 and TaBle 1, and all such variations are to be considered
as having been specifically disclosed. In order to avoid redundancy, such variations are not set forth here.
Although genes and corresponding proteins can be prepared by the totally synthetic techniques dis¬ cussed above, in preferred embodiments of the invention genetic information is obtained from natural sources and identified as described herein. The genetic mater¬ ial is first obtained in the form of a gene library, using any of numerous existing techniques. The first of these is to randomly shear genomic DNA and insert this sheared material into expression vectors, e.g., λgtll. If enough recombinants are generated, there is a good probability of having at least one recombinant in the population which is expressing a fusion protein corresponding to an antigen of inter¬ est. In practice, for a genome the size of the present virus (about 10 kbp, as DNA) at least about 6×10^ inde¬ pendent recombinants are needed. This allows for the entire genome to be represented by recombinants with an average insert size of 100 bp where at least one insert will exist with one of its ends falling within any 10- base-pair region. Allowing for only 1 in 6 such inser¬ tions being in the correct orientation and reading frame, functional recombinants should exist in such a library with fusions corresponding to approximately every 10 base pairs.
A second strategy for preparing gene libraries is to make complementary DNA (cDNA) copies of the total RNA of the virus and to clone these as recombinant molecules in expression vectors. Use of a cDNA library to obtain genetic information for use in the present invention is preferred. Such a library has been generated from NANB-infected human plasma and screened with serum from a NANB-infected human. Among the re¬ combinants expressing determinants reactive with the serum are those described in Figures 1 to 4.
Polyclonal antisera to NANB can be used to screen a cDNA library in order to locate the desired genetic material. cDNA fragments are inserted into an expression vector and after transformation into a suit- able host, the host may be screened for proteins which bind to the polyclonal antisera. Recombinants initial¬ ly identified in this manner can be isolated. The resulting clones may then be used as probes to further search the library for larger fragments or partially overlapping fragments until the complete cDNA is identified.
The NANB genetic material can be used for the production of full fragments or of modified peptides using standard techniques of manipulating and growing unicellular microorganisms. Antigens which are candi¬ dates for vaccine development and/or diagnostic re¬ agents will include those recognized by serum from in¬ fected patients. Additionally, any of the genetic sequences can be used as probes in hybridization assays.
Although the techniques set forth above, when used in combination with the knowledge of those skilled in the art of genetic engineering and the previously stated guidelines, will enable isolation of the desired genetic material and its use in recombinant DNA vectors in conjunction with the disclosed sequence, other methods which lead to the same result are also known and may be used in the preparation of recombinant DNA vectors of this invention. Expression of protein, e.g., for use in vac¬ cines, can be enhanced by including multiple copies of the gene in a transformed host, by selecting a vector known to reproduce in the host (such as pUC8; ptacl2; pIN-III-ompAl, 2, or 3; pOTS; pASl; or pKK223-3), thereby producing large quantities of protein from exogenous inserted DNA or by any other known means of enhancing peptide expression. In all cases, a viral
protein will be expressed when the DNA sequence is functionally inserted into the vector. By “function¬ ally inserted” is meant in proper reading frame and orientation, as is well understood by those skilled in the art. Typically, a gene will be inserted downstream from a promoter and will be followed by a stop codon, although production as a hybrid protein (possibly followed by cleavage) may be used, if desired.
In addition to the above# general procedures which can be used for preparing recombinant DNA mole¬ cules and transformed unicellular organisms in accor¬ dance with the practices of this invention, other known techniques and modifications thereof can be used in carrying out the practice of the invention. In partic- ular, techniques relating to genetic engineering have recently undergone explosive growth and development. Many recent U.S. patents disclose plasmids, genetically engineered microorganisms, and methods of conducting genetic engineering which can be used in the practice of the present invention. For example, U.S. Patent No. 4,273,875 discloses a plasmid and a process of isolat¬ ing the same. U.S. Patent No. 4,304,863 discloses a process for producing bacteria by genetic engineering in which a hybrid plasmid is constructed and used to transform a bacterial host. U.S. Patent No. 4,419,450 discloses a plasmid useful as a cloning vehicle in re¬ combinant DNA work. U.S. Patent No. 4,362,867 dis¬ closes recombinant cDNA construction methods and hybrid nucleotides produced thereby which are useful in cloning processes. U.S. Patent No. 4,403,036 discloses genetic reagents for generating plasmids containing multiple copies of DNA segments. U.S. Patent No. 4,363,877 discloses recombinant DNA transfer vectors. U.S. Patent No. 4,356,270 discloses a recombinant DNA cloning vehicle and is a particularly useful disclosure for those with limited experience in the area of gene¬ tic engineering since it defines many of the terms used
in genetic engineering and the basic processes used therein. U.S. Patent No. 4,336,336 discloses a fused gene and a method of making the same. U.S. Patent No. 4,349,629 discloses plasmid vectors and the production 5 and use thereof. U.S. Patent No. 4,332,901 discloses a cloning vector useful in recombinant DNA. Although some of these patents are directed to the production of a particular gene product that is not within the scope of the present invention, the procedures described
I.Q therein can easily be modified to the practice of the invention described in this specification by those skilled in the art of genetic engineering by substi¬ tution of a subject sequence for the existing open reading frame sequence.
15 The implications of the present invention are significant in that unlimited supplies of NANB viral proteins and genetic material of the subject strain will become available for use in the development of hybridization assays or in any other type of assay
20 utilizing these materials as a reagent for use in diagnosis, immunization, therapeutics, and research. Methods of using genetic material in a hybridization assay and equipment for expansion and amplification of genetic material are commercially available in the PCR
25 system (Perkin-Elmer Cetus).
Particularly contemplated is the isolation of genes and viral genomes that can express protein from the subject virus using oligonucleotide probes based on the principal and variant nucleotide sequences dis-
30 closed herein. In use, the probes are typically labeled in a detectable manner (e.g., with a radio- nuclide, e.g., 32P, 3H, or with biotin) and are incubated with single-stranded DNA or RNA from the organism in which a sequence is being sought.
35 Hybridization is detected by means of the label after single-stranded and double-stranded (hybridized) DNA (or DNA/RNA) have been separated (typically using
nitrocellulose paper). Hybridization techniques suit¬ able for use with oligonucleotides are well known. Identity of virus or genetic material obtained from any source with the virus and genetic material of the invention can be confirmed by hybridization assays using probes prepared from the genetic sequences de¬ scribed herein.
Although probes are normally used with a detectable label that allows easy identification, unlabeled oligonucleotides are also useful, both as precursors of labeled probes and for use in methods that provide for direct detection of double-stranded DNA (or DNA/RNA), such as absorption onto nitrocellu¬ lose. Accordingly, the term “oligonucleotide probe” refers to both labeled and unlabeled forms.
Additionally, it is possible to purify virus articles from any source and reduce the amount of •screening necessary for identifying virus particles and genetic material associated with NANB hepatitis by fractionating, according to buoyant density, biological samples suspected of containing virus, such as a viral pellet obtained from serum or other bodily fluid of an anthropoid infected with NANB hepatitis. By selecting fractions of the proper buoyant density, samples are enriched for the specific virus of the invention.
Virtually 100% of a titered inoculum may be recovered from the buoyant density fractions described herein.
Using such techniques, clones have been prepared and characterized as making an immuno-reactive protein recognized by NANB antiserum (a s-gal fusion product). The genetic material is exogenous to both human and chimpanzee genomes (both infected and uninfected) and, after amplification of the genetic material extracted from buoyant density fractionated serum, is positive for hybridization with a sample obtained from an NANB-infected chimpanzee and negative in the same analysis when tested against amplified
genetic material obtained from a control chimpanzee infected with hepatitis B virus.
As a means of propagating relatively large amounts of viral genomic material, viruses of the invention can be cultured iii vitro using a hybrid cell line susceptible to infection by the virus. Immortal¬ ized virus-specific tissue cells which can be used to culture the NANB viruses of the invention are specific¬ ally described in U.S. Application Serial No. 846,757, filed April 1, 1986. Techniques for obtaining virus particles from cell culture are described in the above- identified application and in U.S. Patent No. 4,464,474 which disclosure is hereby incorporated by reference. The general methods for infecting and cultur- ing the hybrid cells with a selected human infectious virus are as follows: Plasma from a human or other NANB-infected source such as a chimpanzee is used to infect the hybrid cells, and viral infection is followed by monitoring a virus-related cell change over time in culture. NANB virus infection is characterized by the appearance of virus-specific antigens, so the viral infection is properly followed by immunological methods for detecting antigens. After viral infection and propagation, the virus can be isolated, if desired, by conventional means for releasing and purifying virus particles from cells. For example, virus particles may be isolated by lysing the cells and subjecting the lysate to the technique of fractionating samples according to buoyant density, as described below, without additional purification techniques that might disrupt virus particles. The isolated particles will reproduce the virus-related cell change when uninfected hybrid cells are exposed to virus particles.
It may be desirable for a variety of reasons to further purify the particles present in a sample containing particles of the invention. For example, if a virus particle is to be treated and employed as a
vaccine or in an immunoassay, there ordinarily should be as little in the way of extraneous protein contami¬ nation as possible. Thus, the particle should be substantially free of primate proteins. NANB viral antigens may be obtained from a variety of sources. The antigen may be present on an intact virus particle, a partially degraded virus particle, a protein- or carbohydrate-containing molecule in solution, or any other physical form, including an antigen that has been combined either chemically or physically with particle or solid surfaces, such as by attaching antigens to the surface of a test tube or to suspended particles, such as red blood cells or latex particles. An antigen of the invention is defined as a substance containing at least one epitopic site of a virus particle.
To obtain NANB viral antigens, the antigens, whether soluble or in some other form, are typically first separated from water insoluble contaminants having greater dimensions or different density than the intact particles, such as animal cells and cell debris and cellular microrganisms, such as bacteria. This ■ gross separation is generally accomplished by low-speed centrifugation or by filtration using standard techniques. Ordinary filters having an average pore diameter of 0.45 microns are useful in retaining gross contamination and passing through the antigens.
Additionally, antigens of the invention may be separated from undesired water-soluble materials after gross contamination is removed. Where it is desired to recover either intact virus particles or their water- insoluble fragments, it is convenient to simply remove all water soluble constituents from the sample. Suit¬ able techniques include ultrafiltration through a membrane, use of selective flocculating or protein- precipitating agents (such as polyethylene glycol and ammonium sulfate), and chromatography. Chromatography
is the most versatile method since it can be -readily scaled up for commercial manufacture of antigen. Gel chromatography systems using cross-linked dextran beads are typical of the materials used. A column of a suit- able gel can be selected which will permit diffusion of proteins and low molecular weight substances into the void volume of the gel beads, thereby retarding the progress of these contaminants through the column, while allowing whole virus particles to pass through virtually unimpeded. When a particular antigen is de¬ sired, other gel sizes can be selected to provide for isolation of an antigen of any particular size. The gel which is selected will thus be a matter of routine experimentation. Any of the techniques described herein can be combined as desired. For example, isolation of particles on a cesium chloride or sucrose density gradient can be followed by disruption of particles using any of a variety of techniques and isolation of a viral antigen on gel electrophoresis, selecting for proteins binding to antibodies, e.g., antisera, specific for NANB antigens.
One technique that is particularly suitable for isolating soluble protein antigens or particle fragments is affinity chromatography. Antibodies capable of binding antigens of the invention are co- valently linked or adsorbed to an insoluble support using conventional procedures. The coupled antibody is placed in a column. A sample containing antigen is passed through the column, where it binds to the coupled antibody. The immunologically-bound antigen is washed with buffer and can then be released by, for example, changing the ionic strength or pH of the wash buffer. Generally, an acidic pH is effective for releasing the bound antigen. The technique is highly effective in separating closely related proteins from the antigens of the invention.
Antigens of the invention can be used as a vaccine. A preferred starting material for preparation of a vaccine is the particle antigens produced by tis¬ sue culture of the infectious virus. The antigens are preferably initially recovered as intact particles as described above. However, it is also possible to pre¬ pare a suitable vaccine from particles isolated from other sources or non-particle recombinant antigens. When non-particle antigens are used (typically soluble antigens), proteins native to the viral envelope or viral capsid are preferred for use in preparing vac¬ cines. These proteins can be purified by affinity chromatography, also described above.
If the purified protein is not immunogenic per se, it can be bound to a carrier to make the protein immunogenic. Carriers include bovine serum albumin, keyhole limpet hemocyanin and the like. It is desir¬ able, but not necessary to purify antigens to be sub¬ stantially free of human protein. However, it is more important that the antigens be free of proteins, viruses, and other substances not of human origin that may have been introduced by way of, or contamination of, the nutrient medium, cell lines, tissues, or patho¬ logical fluids from which the virus is cultured or obtained.
Vaccination can be conducted in conventional fashion. For example, the antigen, whether a viral particle or a protein, can be used in a suitable diluent such as water, saline, buffered salines, complete or incomplete adjuvants, and the like. The immunogen is administered using standard techniques for antibody induction, such as by subcutaneous administra¬ tion of physiologically compatible, sterile solutions containing inactivated or attenuated virus particles or antigens. An immune response producing amount of virus particles is typically administered per vaccinizing injection, typically in a volume of one milliliter or less.
In addition to use as a vaccine, the composi¬ tions can be used to prepare antibodies to NANB virus particles. The antibodies can be used directly as antiviral agents. To prepare antibodies, a host animal is immunized using the virus particles or, as appro¬ priate, non-particle antigens native to the virus particle are bound to a carrier as described above for vaccines. The host serum or plasma is collected following an appropriate time interval to provide a composition comprising antibodies reactive with the virus particle. The gamma globulin fraction or the IgG antibodies can be obtained, for example, by use of saturated ammonium sulfate or DEAE Sephadex, or other techniques known to those skilled in the art. The antibodies are substantially free of many of the adverse side effects which may be associated with other anti-viral agents such as drugs.
The antibody compositions can be made even more compatible with the host system by minimizing potential adverse immune system responses. This is accomplished by removing all or a portion of the Fc portion of a foreign species antibody or using an antibody of the same species as the host animal, for example, the use of antibodies from human/human hybridomas (see below).
The antibodies can also be used as a means of enhancing the immune response since antibody-virus complexes are recognized by macrophages. The anti¬ bodies can be administered in amounts similar to those used for other therapeutic administrations of anti¬ body. For example, pooled gamma globulin is admini¬ stered at 0.02-0.1 ml/lb body weight during the early incubation of other viral diseases such as rabies, measles and hepatitis B to interfere with viral entry into cells. Thus, antibodies reactive with the NANB virus particle can be. passively administered alone or in conjuction with arϊ ther anti-viral agent to a host
infected with a NANB virus to enhance the immune response and/or the effectiveness of an antiviral drug. Alternatively, anti-NANB-virus antibodies can be induced by administering anti-idiotype antibodies as immunogens. Conveniently, a purified anti-NANB-virus antibody preparation prepared as descibed above is used to induce anti-idiotype antibody in a host animal. The composition is administered to the host animal in a suitable diluent. Following administration, usually repeated administration, the host produces anti- idiotype antibody. To eliminate an immunogenic response to the Fc region, antibodies produced by the same species as the host animal can be used or the Fc region of the administered antibodies can be removed. Following induction of anti-idiotype antibody in the host animal, serum or plasma is removed to provide an antibody composition. The composition can be purified as described above for anti-NANB-virus antibodies, or by affinity chromatography using anti-NANB-virus antibodies bound to the affinity matrix. The anti- idiotype antibodies produced are similar in conforma¬ tion to the authentic NANB antigen and may be used ‘to prepare an NANB vaccine rather than using a NANB particle antigen. When used as a means of inducing anti-NANB- virus antibodies in a patient, the manner of injecting the antibody is the same as for vaccination purposes, namely intramuscularly, intraperitoneally, subcutane- ously or the like in an effective concentration in a physiologically suitable diluent with or without adju¬ vant. One or more booster injections may be desirable. The anti-idiotype method of induction of anti-NANB- virus antibodies can alleviate problems which may be caused by passive administration of anti-NANB-virus antibodies, such as an adverse immune response, and those associated with administration of purified blood components, such as infection with other as yet
uncharacterized agents.
In addition to therapeutic uses, the particles and antigens of the invention, as well as the genetic material, can be used in diagnostic assays. Methods for detecting the presence of NANB hepatitis comprise analyzing a biological sample such as a blood sample or liver biopsy specimen for the presence of an analyte associated with NANB hepatitis virus. The analyte can be a nucleotide sequence which hybridizes with a probe comprising a sequence of at least about 16 consecutive nucleotides, usually 30 to 200 nucleotides, up to substantially the full sequence of the cDNA sequence shown in Figures 1 to 5. The analyte can be RNA or cDNA. The analyte can be a virus particle having at least one of the following characteristics: obtainable from cells susceptible to infection with NANB hepa¬ titis; capable of inducing expression of virus-specific surface antigen in a cell susceptible to infection by the particle, the surface antigen being recognized by serum from a host infected with NANB and not by serum from a non-infected host; having a buoyant density of from about 1.09 to 1.11 gm/cm2. The virus particle can be further characterized as having an RNA viral genome comprising a sequence at least about 80% homologous to a sequence of at least 12 consecutive nucleotides of the sequences in Figures 1 to 5, usually at least about 90% homologous to at least about 60 consecutive nucleo¬ tides within the sequence, and may comprise a sequence substantially homologous to the sequences in Figures 1 to 5. The analyte can comprise an antibody which recognizes an antigen, such as a cell surface antigen, on a NANB virus particle. The analyte can also be a NANB viral antigen. In order to detect an analyte, where the analyte hybridizes to a probe the probe may contain a detectable label. Likewise, where the analyte is an
antibody or an antigen, either a labelled antigen or antibody, respectively, can be used to bind to the analyte to form an immunological complex, which can then be detected by means of the label. Typically, methods for detecting analytes such as surface antigens and/or whole particles are based on immunoassays. Immunoassays can be conducted either to determine the presence of antibodies in the host that have arisen from infection by NANB hepatitis virus or by assays that directly determine the presence of virus particles or antigens. Such techniques are well known and need not be described here in detail. Examples include both heterogeneous and homogeneous immunoassay techniques. Both techniques are based on the formation of an immunological complex between the virus particle or its antigen and a corresponding specific antibody. Heterogeneous assays for viral antigens typically use a specific monoclonal or polyclonal antibody bound to a solid surface. Sandwich assays are becoming increas- ingly popular. Homogeneous assays, which are carried out in solution without the presence of a solid phase, can also be used, for example by determining the difference in enzyme activity brought on by binding of free antibody to an enzyme-antigen conjugate. A number of suitable assays are disclosed in U.S. Patent Nos. 3,817,837, 4,006,360, 3,996,345.
When assaying for the presence of antibodies induced by NANB viruses, the viruses and antigens of the invention can be used as specific binding agents to detect either IgG or IgM antibodies. Since IgM anti¬ bodies are typically the first antibodies that appear during the course of an infection, when IgG synthesis may not yet have been initiated, specifically distin¬ guishing between IgM and IgG antibodies present in the blood stream of a host will enable a physician or other
investigator to determine whether the infection is recent or chronic.
The genetic material of the invention can it¬ self be used in numerous assays as probes for genetic material present in naturally occurring infections. One method for amplification of target nucleic acids, for later analysis by hybridization assays, is known as the polymerase chain reaction or PCR technique. The PCR technique can be applied to detecting virus particles of the invention in suspected pathological samples using oligonucleotide primers spaced apart from each other and based on the genetic sequence set forth in Figures 1 to 5. The primers are complementary to opposite strands of a double stranded DNA molecule and are typically separated by from about 50 to 450 nt or more. This method entails preparing the specific oli¬ gonucleotide primers and then repeated cycles of target DNA denaturation, primer binding, and extension with a DNA polymerase to obtain probes of the desired length. Extension products generated from one primer serve as additional target sequences for the other primer. The degree of amplification of a target sequence is controlled by the numbe-r of cycles that are performed and is theoretically calculated by the simple formula 2n where n is the number of cycles. Given that the average efficiency per cycle ranges from about 65% to 85%, 25 cycles produce from 0.3 to 4.8 million copies of the target sequence. The PCR method is de¬ scribed in a number of publications, including Saiki et al. , Science (1985) 3£:1350″1354– Saiki et al., Nature (1986) 324:163-166; and Scharf et al., Science (1986) 23J3:1076-1078. Also see U.S. Patent Nos. 4,683,194; 4,683,195; and 4,683,202.
For both i_n vivo use of antibodies to NANB- virus particles and proteins and anti-idiotype anti¬ bodies and diagnostic use, it may be preferable to use monoclonal antibodies. Monoclonal anti-virus particle
antibodies or anti-idiotype antibodies can be produced as follows. The spleen or lymphocytes from an immunized animal are removed and immortalized or used to prepare hybridomas by methods known to those skilled in the art. To produce a human-human hybridoma, a human lymphocyte donor is selected. A donor known to be infected with a NANB virus (where infection has been shown for example by the presence of anti-virus anti¬ bodies in the blood or by virus culture) may serve as a suitable lymphocyte donor. Lymphocytes can be isolated from a peripheral blood sample or spleen cells may be used if the donor is subject to splenectomy. Epstein- Barr virus (EBV) can be used to immortalize human lymphocytes or a human fusion partner can be used to produce human-human hybridomas. Primary iri vitro immunization with peptides can also be used in the generation of human monoclonal antibodies.
Antibodies secreted by the immortalized cells are screened to determine the clones that secrete anti- bodies of the desired specificity. For monoclonal anti-virus particle antibodies, the antibodies must bind to NANB virus particles. For monoclonal anti-‘ idiotype antibodies, the antibodies must bind to anti- virus particle antibodies. Cells producing antibodies of the desired specificity are selected.
The invention now being generally described, the same will be better understood by reference to the following examples which are provided for purposes of illustration only and are not to be considered limiting of the invention unless so specified. i
EXPERIMENTAL
Two hybrid liver cell cultures infected with :”|ANB virus particles were deposited with the American
Type Culture Collection (ATCC), 12301 Parklawn Drive,
Rockville, Maryland 20882, on June 24, 1988. The two
hybrid cultures are GLH03 and GLH04, and were given ATCC accession numbers CRL 9754 and CRL 9755, respec¬ tively. An uninfected hybrid liver-cell culture GLH02 was deposited with the ATCC on March 26, 1986 and given ATCC accession number HB 9027.
Example 1 Preparation of cDNA Clone from NANB Particles Isolated from Human Serum Serum from human patients diagnosed as having
NANB hepatitis was centrifuged at 30,000 rpm for 2-1/2 hrs at 5°C in an SW40 rotor (Beckman). The supernatant was removed and discarded and the pellet solubilized in 50 mM sodium acetate buffer, pH 4.8, containing 1% sodium dodecylsulfate (SDS). The RNA was selectively extracted using phenol equilibrated in the same buffer without SDS. The nucleic acid in the aqueous phase was then precipitated using two volumes of absolute ethanol. The RNA was reverse-transcribed into double- stranded cDNA using a DNA synthesis kit following the procedure specified by the manufacturer (Boehringer- Mannheim Bioche icals, Indianapolis, Indiana) except for the substitution of random primers for the oligo dt primer provided in the kit. The dsDNA obtained was ligated to EcoRI linkers and after generation of the cohesive EcoRI sites, was inserted into λgtll as described by the supplier (ProMega Biotech, Madison, Wisconsin) . The plaques were screened with NANB- infected human antisera and positive clones were isolated. The clones were then rescreened using the NANB-infected human antisera and plaque-purified.
Analysis of the sequences shown in Figures 1 to 4 using available sequence homology search programs revealed that the cloned sequences were unlike any entered in the data bank (GenBank versions 54 and
57). No homology was found to polypeptide sequences contained in GenBank version 52. Analysis of the DNA
sequences shown in Figure 5 (against GenBank version 57) showed no significant homology.
Example 2 Purification of NANB Virus Particles
From Infected Chimpanzee Plasma NANB virus particles originally derived from human plasma were isolated as follows: A plasma inoculum from a chimpanzee inoculated with infected plasma comprising NANB virus particles originating from a patient diagnosed as having NANB hepatitis but carried in chimpanzees was layered onto the top of a linear 20-55% sucrose gradient in Tris HCl 0.01 M, pH 8.0, containing 0.001 M EDTA, 0.1 M sodium chloride. The gradient was prepared using a Hoefer gradient maker. The chimpanzee inoculum contained 10° chimpan¬ zee infectious doses (CID) of NANB virus particles. The gradient was centrifuged for 18 hrs at 30,000 rpm at 5°C in an SW40 rotor. Following fractionation of the gradient, the fractions were analyzed for infectiv- ity by reinjection into chimpanzees. Fractions having a buoyant density of 1.09 to 1.11 gm/cm3 were infec¬ tious at a dilution of 1:10 , based upon alanine amino transferase (ALT) elevation at about 30 days post- inoculation into the chimpanzee.
Example 3 Preparation of cDNA from Purified Virus Particles The virus particles obtained as described in Example 2, having a buoyant density of from 1.09 to 1.11 gm/cm3 were used to prepare cDNA as described in Example 1. The cDNA obtained was then amplified using a technique described in co-owned patent Application Serial No. 208,512, filed June 17, 1988, which disclosure is incorporated herein by reference. As a control, amplified cDNA was prepared from the buoyant density fractionated plasma of a chimpanzee chronically
infected with HBV in the same manner as for the NANB cDNA. Infected and control amplified cDNAs were electrophoresized using an agarose gel (2%) and then transferred to nitrocellulose filters by the method of Southern (J. Mol. Biol. (1975) 8:503).
Clone #30 (obtained as in Example 1; sequence as in Figure 1) was radiolabeled using 2P nucleotides and a random primer kit according to the instructions provided by the kit manufacturer (Boehringer-Mannheim Biochemicals, Indiannapolis, Indiana). The radio- labeled clone #30 was then used as a hybridization probe against a filter containing the amplified cDNAs from the fractionated virus particles. Specific hybridization, as detected by autoradiography, was evident only with the cDNA prepared from the NANB- infected chimpanzee. It was thus demonstrated that the molecular clone #30 isolated from a NANB-infected human source (identified by using serum from a different NANB-infected human and characterized as exogenous to the human and chimpanzee genomes) detected homologous sequences present in cDNA prepared from an enriched source of documented infectious NANB particles passaged in chimpanzees, but originating in an infected human. Clones PT’2, PT’8 and PT’9 also hybridized specifically to cDNA prepared from the NANB-infected chimpanzee.
Example 4 Infection of Immortalized Liver Cells With NANB Virus Hybrid liver cells were plated at 1 x 10° cells/well in a 24-well tray and overlaid with 100 ul of plasma from a chimpanzee known by its passage into a second chimpanzee to contain NANB viral agent(s); or (b) human plasma from an individual with acute post- transfusion NANB hepatitis. After an initial incuba¬ tion of the chimpanzee serum and cells, 0.5 ml of growth medium containing IMDM and 20% FCS was added to
each well and the cells were grown at 37°C in a humidified 7% C02 incubator. The cultures were fed with growth medium every 3 to 4 days, and liver hybrid cells were removed every week to assay for the presence of NANB.
To detect the presence of virus particles, the cells were analysed for expression of NANB virus specific surface antigens. The method is as follows: An aliquot of the culture medium containing about 1 x IO7 cells was removed from a culture well and the cells pelleted by centrifugation at 200 x g for 10 minutes. After washing the cells three times with PBS, the cells were resuspended to 2.5 x 10° cells/ml and 10 ul of the cell suspension were dropped on a micro- scope slide and allowed to air-dry. The dried cells were then fixed on the slide by addition of acetone for one minute. To minimize non-specific binding, the slides were preincubated with normal goat serum- (1:10 dilution) for 30 minutes at room temperature in a moist chamber. The slides were washed three times with PBS and once with distilled water, then 70 ul of test serum obtained from one of the panel chimpanzees (identified at the left in Table 2, see below) were added to the slides. Each serum sample had been preabsorbed with uninfected liver hybrid cells (10’ cells per ml serum) to remove serum factors which tended to bind to the cells non-specifically. The slides containing the added serum were incubated in moist chambers for 90 minutes at room temperature, then again washed three times with PBS and once with distilled water.
Goat anti-human IgG and IgM conjugated with fluorescein isothiocyanate (FITC-conjugated antibody) were obtained from a commercial source (Zymed Labs). They were each diluted with PBS to a final concentra- tion of about 1 ug antibody/ml. Either anti-IgM or anti-IgG FITC-conjugated antibody (70 ul) was added to the washed cells, and the slides were incubated at room
temperature for 30 minutes. After washing with PBS and distilled water as above, the slides were mounted with one drop of 50% glycerol in PBS and observed under a fluorescence microscope. The cells were scored for weak (+), intermediate (++), and strong (+++) fluorescence.
The first indications of immunofluorescence occurred at about 6 to 8 weeks after initial cell infection with each virus source. The results shown in Table 2 were obtained 6 weeks post infection with chimpanzee plasma known to contain NANB agent(s).
Table 2
Expression of NANB Viral Cell Surface Antigens in Immortalized Liver Cells Infected witH NANB Virus
Reactivity with Liver Hybridomas
Infected Uninfected
++
+++
■* These animals are pre-NANB inoculation.
As seen in the right hand columns in Table 2, specific immunofluorescence was observed only with serum from NANB-infected animals, and not with serum from uninfected animals or those infected with HBV.
The results indicate that (a) the liver hybrid cells are infectable by NANB virus, (b) the infected hybrid cells are expressing a virus-specific surface antigen which is recognized by NANB serum antibody from chimps with known NANB infection, and (c) an incubation period of between about 4 to 6 weeks is required for surface antigen expression.
The results shown in Table 2 were obtained with anti-IgG antibody. No immunofluorescence was observed with FITC-conjugated anti-IgM antibody, as would be expected if the chimpanzee anti-NANB anti¬ bodies were IgG antibodies. Plasma from a patient with acute post-transfusion NANB gave a result similar to those obtained above with plasma from infected chim- panzees. After 6 weeks, liver hybrids infected using patient plasma showed specific immunofluorescence with serum from a NANB-infected chimpanzee, but not with control (uninfected) chimpanzee serum.
Example 5
Recovery of NANB Infectious Virus Particles from Hybrid Liver Cells The NANB-infected hybrid cells were also examined for the presence of infectious virus. Infected hybrid cells (obtained as described in Example 4) 12 weeks post infection were collected by centrifu- gation, then washed three times with PBS. The cells were resuspended in PBS to about 5 x 10° cells/ml and sonicated to clarity. The supernatants (0.5 ml/well) were then inoculated on uninfected hybrids and cultured in the manner described in Example 4 for cell infection by chimpanzee plasma. Cell-free lysates can also be prepared by hypotonic lysis or freeze-thawing. After about 6 to 8 weeks in continuous culture, specific immunofluorescence was observed with chimpanzee NANB serum, but not with serum from uninfected animals.
demonstrating that the cell particles so propagated retained their infectivity.
Example 6 Stability of Viral Infectivity of
NANB Virus Particles Propagated in Hybrid Liver Cells Molecular clones from NANB-infected cells are isolated to determine if in vitro passage leads to the generation of defective viral particles, with resultant attenuation of viral infectivity. The method is as follows:
Infected cells are grown in exponential phase and then harvested by centrifugation for 10 minutes at 3,000 rpm. A cell-free lysate is prepared from 5 x IO8 cells by 3 successive cycles of freezing on dry ice/ethanol and thawing at room temperature. The lysate is clarified by centrifugation at 10,000 x g for 15 minutes in a microfuge. The supernatant is then loaded onto a linear sucrose density gradient as described above (see Example 2). The fractions having a buoyant density of from 1.09 to 1.11 gm/cm3 are collected and particles extracted for RNA as described above in Example 3. After conversion to cDNA, and amplification as described in Example 3, the amplified cDNA is analysed by Southern blot hybridization to confirm the presence of NANB homologous sequences. The probes used are the cDNA clones whose sequence appears in Figures 1 to 4. The material is then cloned into λgtlO and molecular clones selected by hybridization using the molecular clones shown in Figures 1 to 4 as a probe. The primary nucleotide sequence of molecular clones derived from infected hybrid liver cells is then analysed to determine whether defective viral particles have been generated during passage in vitro.
All publications and patent applications mentioned in this specification are indicative of the
level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.
Claims (30)
WHAT IS CLAIMED IS:
1. A hybrid cell comprising: non-A, non-B (NANB) viral genomic material, said cell being produced by the method comprising: infecting said hybrid cell with a sample comprising infectious NANB virus particles.
2. The hybrid cell according to Claim 1, wherein said infectious virus particles have a buoyant density of about 1.09 to about 1.11 gm/cm3.
3. A method for propagating non-A, non-B hepatitis (NANB) viral genomic material, said method comprising: growing a hybrid cell line infected with NANB viral genomic material for a sufficient time for said viral genomic material to propagate.
4. The method according to Claim 3, wherein said cell line is infected by contacting uninfected hybrid cells with a sample comprising infectious NANB virus particles.
5. The method according to Claim 4, wherein said sample comprises : virus particles and antigens associated with non-A, non-B hepatitis separated from contaminants based upon buoyant density collecting as a non-A, non-B fraction, material having a buoyant density of about 1.07 to about 1.13 gm/cm3.
6. The method of Claim 4, wherein said fraction contains material having a buoyant density of from about 1.09 to about 1.11 gm/cm3.
7. Virus particles isolated from a biological sample, said virus particles being characterized as being obtainable from cells susceptible to infection with PT-non-A non-B (NANB) hepatitis virus and having a bouyant density of from about 1.09 to 1.11 gm/cm3.
8. The virus particles according to Claim 7, wherein said biological sample is plasma or an hepatocyte from a host infected by PT-NANB hepatitis virus.
9. The virus particles according to Claim 8, wherein said host is human.
10. The virus particles according to Claim 7, wherein said particles are further characterized as having an RNA viral genome comprising a sequence at least 80 percent homologous to a sequence of at least 12 consecutive nucleotides within one of the following DNA sequences:
1 ACACAACCAAATTCTTGGTTCCAGCGCCAACCTGAAACCAAA 42
43 AAAGTGGCAAATATTGCCGGGCAAGCGTCGATTGCTTCGACC 84
85 GCCTATGTGAGCCAAGATGCGGCCATTTCGGCCTACAATAAA 126
27 GTAAAAAATGCTGTGGTCACCGTGCAAAACTTGCAAAAGAAT 168
169 GCGGCCCAAACCCCAGATGGTTTTGCGGGGTTGTTTGGTCAA 210
211 TCAGGGCGTCAAAAGCAAGCCGATAATAATGGCCAAGTTGAA 252
253 ACTGCCTCAGAAGGCTCT 270 or
1 AAAAATAACAAGATCTTACATTTACGGAAATCTGCGACAAAA 42 43 GTTTCCAAATATAAGAJ?CAAAAAGTTAAGTGTTGGTGTCGCC 84 85 TCCGTTCTGGTGGGGGCCACTTTCTTCCTTGGTTCGACAGCG 126 127 AGTGCAAGTGCTTCTGATGAGCAACTCGCTGATAAGCAGGCA 168 169 GGGGTCACACAACAAACTGATCAAAATGCAACAAACACAAAT 210 211 GATCGGGTATTAAAGTTTGACAATGCAACGTCAACGGCCACA 252 253 ACGGATAATGCTGATTCTAGTGCGGCCAAAATGTCAAACGTT 294 295 GCGCAAGCTGACAATTCAGCCAACAATGCAACAGTAGCTAAT 336 337 AATCTTGATAAAAAATCAATTACCGATTCTACATTATCCAAT 378 379 AATAACGATTTAAAATCAACTGAAATGCAATCAACTGTTACT 420 421 GACCAAGCAGCAGCTGACGATGCAAGTACTGCTGATCAAACA 462 463 GCAACTGAAAAGCAAGCAACTGTGACCAATCAAGCCACAGTT 504 505 GATAACACAGTAAATACTGCTGACCAAGCAACTCAAGCAGCA 546 547 GCTGAAAAGACAACAACGCCTGCAAGTACTGCTGCCAACACG 588 589 CAAGCAGCTGCACTAGTTGCAACGCTACGTGCCGCAGCAACT 630 631 GCGGATACAAGTACGACGACAACTGTTAACAACTGGACT 669 or
1 CCATCGGCTTCCATCCAGGAAGCAATGGATAAGCAGTTAACG 42 43 GCTGATCGTGAACGAGTGGCAACTATTGCAAAAGCCGAAGGG 84 85 GAGGCACGCTCCATCGAACTCACAACCAAGGCTAAAAATGAC 126 127 GCGTTGATGGCGACGGCGAAAGCCGAAGCTGACGCGACGAAA 168 169 ACCCGTGCTGATGCCGAACGTTACCGAATCGATACGGTACAA 210 211 GCTGGTTTGGCTGGGGCGGATGACAAGTACTTCCAAAACCAA 252 253 TCCATTAACGCATTCGCGACGTTACCCAAT 282 or
ATCGAGAGCAACGCACTGGCAGTGTCCAACCTGGATTTCTGATC CTGTTTTGACCCGCAGTACCCAAAAAGGCCAACGCTCAGCGTTGGCCTTT TTTAATGGCTAAAAAATGACTATGGCGCCAACAGCACCGCCCTCTCCTCG CGGCACAACTCCAGTAAAAAATCCCACACCACCCTCAACCTTACGGATTT GTGCAGTTCCCGGCGGGTGCTGATCCAGTAACTGCGTTGCACAGACTCGC CCGGCAATACACGCACCAGGTCGGGGTCGTCAGCGGCCATGTAGTTGGGC AATACGGCGATACCCAGGCCGGCGCGAGCGGCTTGTTGCTGGGCAATGAC
GCTGGTGCTGCGAAAGGTCACGGTCGGGGTGCGGCAGAAGGTATTGAGGA
ACAGCAGCTCCTGACTGAACAACAGGTCGTCGACGTAGCCGATCCAGTAG
TGGTTGCCA or
GTCATCACGCACAACAGGGGTGTTGAGCGGTGC ACCGAGTTCTTTCCAGTCCGGGAACAATTCGTTCAGCGCACGGGGTTCAA ACACGGCACCGGACAGGATGTGAGCGCCGACTTCGGAGCCTTTTTCGACC ACGCAGACGCTGATTTCCTTACCGGCTTCGGCGGCCTTCTGCTTCAATCG GCAGGCGGCAGACAGGCCTGCCGGGCCAGCGCCGACGATGACCACGTC or
GTTGACCACTCCCTGGCCGTCGAAGCCGGTG GTTCGACCGACGCCTTCGAGAAGAACCGCGCCATCGAAGACCGCCGCAAC GAAGACTGTTTCCACTTTATCGAGTGGACCAAAAAGGCCTTCAAGAACGT CGATGTGATCCGCCGGGCAACGGCATCATGCACCAGATCAACCTGGAGAA AATGTCGCCGGTGATCCAGGTGCGCGACGGCGTAGCTTCCGGATACCTGC . GTCGGCACCGATAGCCACACGCCCACGTGGATGCCTTGGCGTGATCGCAT CGGCTCTGGCGCGTA or
CCCCATAGAGCCCGGACCCATAGACAGCCCTG CCCCATAGACAGTCTGGCCCTATAGACAGCCCAGCCCCATAGAGCCCGGC CCTATAGATAGCCCGGCCCCATACAGCCCGGACCCATAGAGAGCACTGCC CCATAGAGCCCGGACCCATAGAGCCCTGCCCCATAGACAGTC or
GCCAAAGAGTGGCGCACCGACCGTTCCCTCAG CCGCCTCGAAGCCATGCTCGCCGTGGCCAACAAAGACGCCTCCCTGATCA TCACCGGCAACGGTGACGTGGTAGAGCCAGAAAACGGCTTGATCGCCATG GGCTCCGGTGGCGGCTACGCCAGGCTGCGGCCAGTGCGCTGTTGAAGAAA
ACCGACCTGTCGGCCCGTGAAATCGTCGAGACCGCCTTGGGCATCGCTGG
CGATATCTGCGTGTTCACCAACCACAACCTGACCATTGAGGAGCAGGACC
TCGCCGAGTAAGCCGTAGGCTTATTC or
GGCGATGACGGCTGCACCGCAAGCACCAGTA TCAGTCCAGCCAAGTGAAACAGTGACACCTGCACAACCCGTCAAAGTTGC ACCACAAGTGGTTGCAGCGCAACCAACGTCAACACCAACACCAACGGTAA CAGTTGAGACTGTACCATCAACGCCTACGCCAGTGCCACCAACATTGGCA ACGCCACCAATTGCACAACCAGTGGTAACTGCTGCGCCAACTGAAGAAGC AGCCGTTGCCAACCAGTTGTGGGCACGTACGGGACAAAATGCGGTCTTTG CCGTCCTACAACAAGCGAACGGAGACGCTTAGTCGCGTGAAGGCTGCTTG • GTCAGACTTGATTAGTCAATTTGGTGTTGCTGAACAGGCCTTACTGACGA TTGCCGCCCCAGTAGCTGCAAGTGAGGAAGGGCTTGTTTTAGCGTTTGAT TTTCCACCTTTATTGGCGCAAGCTTTACAAGATGCCGCCTTGCAAACGCA ATTACGGACAGCGCTGGCTGCACAACAATTGCCAACAGAAATGGTGTTGA TTACCCAAGATAGCTGGCAACAAGAACGCTCTGATTATGTCGCGCAGTTA AAGGCGGGGACGACTCAACCTTTGAATTTGGCGGATATACCGAGAGTGAG CCAAACAACCACGACCCAGTCGCAAAGTGCACCGACACCAGAGCAAACGG GGCTTG or
TCGGGCCGGTAATGACCACGGCCACCATAGCACCGCGAAGAAGCCTGCGA TGGCGACGCTGGAGGCCATGGTGACGACGCTCCAATCGATGTCCGCGCGC GCTCGGCGGCGCGATCTGCCGGATATCATCCGGCGCACCAGTCGGACGCC GCAGCCGCGCTACCGGCCCGAGAAAGAAGATCGCCGCCGCCCATTCGATG GGGAACG.
11. The virus particles according to Claim 10, wherein said viral genome comprises a sequence at least 90 percent homologous to a sequence of at least 60 consecutive nucleotides within said sequence.
12. A substantially pure polynucleotide having a region substantially complementary to or the same as a segment of at least 12 consecutive nucleotides of a DNA sequence of Claim 10.
13. The polynucleotide according to Claim 12, wherein said polynucleotide comprises substantially the entire sequence of one of said sequences.
14. A PT-non-A, non-B viral antigen defining at least one antigenic determinant, said antigen comprising: a protein encoded in part by a sequence substantially homologous to a DNA sequence of Claim 10 or a complementary sequence.
15. The antigen of according to Claim 14, substantially free of other proteins.
16. A vector comprising a replication system functional in a bacterium, a marker for detection of transformants and a sequence substantially homologous to a sequence of at least 60 nucleotides of a sequence of Claim 10.
17. A method for detecting the presence of a non-A, non-B hepatitis virus, which comprises: analyzing a biological sample to determine the presence of an analyte, wherein said analyte comprises a nucleotide sequence having a sequence which hybridizes with a probe comprising at least 16 consecutive nucleotides of a sequence of Claim 10.
18. A vaccine for immunizing a host against non-A, non-B (NANB) hepatitis viral agent, said vaccine comprising: a viral antigen or an inactivated or attenuated virus particle in a physiologically compatible solution, wherein said antigen or particle is obtained from a cell infected with NANB hepatitis virus.
19. The vaccine according to Claim 18, wherein said viral antigen or said virus particle comprises a protein encoded in part by a sequence substantially homologous to a sequence of Claim 10 and wherein said protein defines at least one antigenic determinant.
20. The vaccine according to Claim 19, wherein said antigenic determinant is recognized by NANB serum antibody from chimpanzees or humans with known NANB infection.
21. An anti-viral agent comprising an antibody composition, wherein said antibodies are capable of binding to a post transfusion non-A, non-B (PT-NANB) hepatitis virus particle, and wherein production of said antibodies is obtained by administering to said host animal an immunogenic composition comprising PT-NANB virus particles isolated from a biological sample, or non-particle antigens native to PT-NANB virus particles, said virus particles being characterized as being obtainable from cells susceptible to infection with PT- NANB.
22. An antiviral agent according to Claim 21, wherein at least a portion of the Fc region of said antibodies has been removed.
23. An anti-viral agent according to Claim 21, wherein said production is immortalized by preparation of a hybridoma cell comprising a cell from said host animal which synthesises said antibodies. r-
24. An antiviral agent according to Claim 23, wherein said hybridoma is a human-human hybridoma.
25. An antiviral agent according to Claim 24, wherein said antibodies are monoclonal antibodies.
26. A hybridoma producing antibodies capable of binding to a post transfusion non-A, non-B (PT-NANB) hepatitis virus particle.
27. A .hybridoma according to Claim 26, wherein antibodies are monoclonal antibodies.
28. An anti-idiotype antibody composition comprising antibodies having a conformation at least substantially similar to a native non-A, non-B (PT-NANB) hepatitis virus antigen, wherein production of said antibodies is obtained by administering to a host animal an immunogenic composition comprising anti-PT-NANB virus antibodies.
29. A method of enhancing the effectiveness of an anti-viral drug in a post-transfusion non-A, non-B (PT-NANB) hepatitis virus-infected host animal treated with said drug, said method comprising: treating said host animal with an anti-PT-NANB antibody composition in conjunction with said drug.
30. The method of Claim 29 wherein said treating comprises inducing said anti-PT-NANB antibody composition in said host animal by administrating to said host animal an anti-idiotype antibody having a conformation at least substantially similar to a native PT-NANB hepatitis virus antigen.
AU40464/89A
1988-07-06
1989-06-28
Post-transfusion, non-a, non-b hepatitis virus and antigens
Abandoned
AU4046489A
(en)
Applications Claiming Priority (8)
Application Number
Priority Date
Filing Date
Title
US21572888A
1988-07-06
1988-07-06
US215728
1988-07-06
US22833488A
1988-08-04
1988-08-04
US228334
1988-08-04
US33470189A
1989-04-06
1989-04-06
US35057089A
1989-05-11
1989-05-11
US350570
1989-05-11
US334701
1994-11-04
Publications (1)
Publication Number
Publication Date
AU4046489A
true
AU4046489A
(en)
1990-02-05
Family
ID=27499018
Family Applications (1)
Application Number
Title
Priority Date
Filing Date
AU40464/89A
Abandoned
AU4046489A
(en)
1988-07-06
1989-06-28
Post-transfusion, non-a, non-b hepatitis virus and antigens
Country Status (5)
Country
Link
EP
(1)
EP0423239A4
(en)
JP
(1)
JPH04501203A
(en)
CN
(1)
CN1041005A
(en)
AU
(1)
AU4046489A
(en)
WO
(1)
WO1990000597A1
(en)
Cited By (2)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
AU623433B2
(en)
*
1988-09-30
1992-05-14
Research Foundation For Microbial Diseases Of Osaka University, The
Non-a, non-b hepatitis virus antigen peptide
AU673135B2
(en)
*
1990-08-25
1996-10-31
New York Blood Center, Inc., The
Non-A, non-B hepatitis virus antigen, diagnostic methods and vaccines
Families Citing this family (36)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US5683864A
(en)
*
1987-11-18
1997-11-04
Chiron Corporation
Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5350671A
(en)
*
1987-11-18
1994-09-27
Chiron Corporation
HCV immunoassays employing C domain antigens
JP2656995B2
(en)
*
1989-03-17
1997-09-24
カイロン コーポレイション
NANBV diagnostics
US5372928A
(en)
*
1989-09-15
1994-12-13
Chiron Corporation
Hepatitis C virus isolates
AT400724B
(en)
1989-12-18
1996-03-25
Wellcome Found
VIRAL POLYPEPTIDE
US7166287B1
(en)
1989-12-18
2007-01-23
Glaxo Wellcome Inc.
Viral agent
US5106726A
(en)
*
1990-02-16
1992-04-21
United Biomedical, Inc.
Synthetic peptides specific for the detection of antibodies to HCV
US5747239A
(en)
*
1990-02-16
1998-05-05
United Biomedical, Inc.
Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
KR940000755B1
(en)
*
1990-02-16
1994-01-29
유나이티드 바이오메디칼 인코오포레이티드
Synthetic peptides specific for the detection of antibodies to hcv
AU7672991A
(en)
*
1990-04-03
1991-10-30
Southwest Foundation For Biomedical Research
Purified hcv and hcv proteins and peptides
US5712087A
(en)
*
1990-04-04
1998-01-27
Chiron Corporation
Immunoassays for anti-HCV antibodies employing combinations of hepatitis C virus (HCV) antigens
AU660925B2
(en)
*
1990-04-06
1995-07-13
Genelabs Technologies, Inc.
Hepatitis C virus epitopes
CA2044296A1
(en)
*
1990-06-12
1991-12-13
Hiroaki Okamoto
Oligonucleotide primers, and their application for high-fidelity detection of non-a, non-b hepatitis virus
EP0464287A1
(en)
*
1990-06-25
1992-01-08
The Research Foundation for Microbial Diseases of Osaka University
Non-A, non-B hepatitis virus genomic cDNA and antigen polypeptide
US5747339A
(en)
*
1990-06-25
1998-05-05
Research Foundation For Microbial Diseases Of Osaka
Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide
WO1992017612A1
(en)
*
1991-03-26
1992-10-15
Baxter Diagnostics Inc.
Assay for non-a non-b hepatitis
FR2677372B1
(en)
1991-06-06
1994-11-10
Pasteur Institut
NUCLEOTIDE AND PEPTIDE SEQUENCES OF A HEPATITIS C VIRUS ISOLATE, DIAGNOSTIC AND THERAPEUTIC APPLICATIONS.
US5866139A
(en)
*
1992-06-04
1999-02-02
Institut Pasteur
Nucleotide and peptide sequences of a hepatitis C virus isolate, diagnostic and therapeutic applications
US5552310A
(en)
*
1992-06-12
1996-09-03
Hiroshi Yoshikura
Replication of hepatitis C virus genome and identification of virus having high infectivity
US5859230A
(en)
*
1992-07-30
1999-01-12
Genelabs Technologies, Inc.
Non-A/non-B/non-C/non-D/non-E hepatitis agents and molecular cloning thereof
AU682335B2
(en)
*
1992-12-29
1997-10-02
Akzo Nobel N.V.
Monoclonal antibodies and anti-idiotypic antibodies to hepatitis C virus
WO1994025064A1
(en)
*
1993-05-04
1994-11-10
THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMANSERVIC ES
Hepatitis c virus cell propagation and related methods
US6051374A
(en)
*
1994-02-14
2000-04-18
Abbott Laboratories
Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use
US6586568B1
(en)
1994-02-14
2003-07-01
Abbott Laboratories
Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use
US5981172A
(en)
*
1994-02-14
1999-11-09
Abbott Laboratories
Non-A, non-B, non-C, non-D, non-E Hepatitis reagents and methods for their use
US6156495A
(en)
*
1994-02-14
2000-12-05
Abbott Laboratories
Hepatitis GB virus recombinant proteins and uses thereof
US5843450A
(en)
*
1994-02-14
1998-12-01
Abbott Laboratories
Hepatitis GB Virus synthetic peptides and uses thereof
US6451578B1
(en)
1994-02-14
2002-09-17
Abbott Laboratories
Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use
US6720166B2
(en)
1994-02-14
2004-04-13
Abbott Laboratories
Non-a, non-b, non-c, non-c, non-d, non-e hepatitis reagents and methods for their use
US6558898B1
(en)
1994-02-14
2003-05-06
Abbott Laboratories
Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use
MX9605666A
(en)
*
1994-05-20
1998-05-31
Genelabs Tech Inc
Hepatitis g virus and molecular cloning thereof.
US5824507A
(en)
*
1994-05-20
1998-10-20
Genelabs Technologies, Inc.
Hepatitis G virus and molecular cloning thereof
US5874563A
(en)
*
1994-05-20
1999-02-23
Genelabs Technologies, Inc.
Hepatitis G virus and molecular cloning thereof
US5709997A
(en)
*
1995-08-14
1998-01-20
Abbott Laboratories
Nucleic acid detection of hepatitis GB virus
US5807670A
(en)
*
1995-08-14
1998-09-15
Abbott Laboratories
Detection of hepatitis GB virus genotypes
US5955318A
(en)
*
1995-08-14
1999-09-21
Abbott Laboratories
Reagents and methods useful for controlling the translation of hepatitis GBV proteins
Family Cites Families (12)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US4464474A
(en)
*
1980-07-09
1984-08-07
Connaught Laboratories Limited
Non-A, non-B hepatitis assay and vaccine
US4702909A
(en)
*
1982-05-05
1987-10-27
Louisiana State University A & M
Non-A, non-B hepatitis antigen, antigen compositions, vaccine and diagnostic reagent
DE3316464A1
(en)
*
1983-05-05
1984-11-08
Heinrich Prof Dr Med Liehr
VIRUSANTIGEN, METHOD FOR ITS DETERMINATION AND APPLICATION IN DIAGNOSIS AND THERAPY (VACCINE)
ZA8410091B
(en)
*
1984-03-02
1985-08-28
Warner Lambert Co
Detection of non-a,non-b hepatitis
US4707439A
(en)
*
1984-10-26
1987-11-17
The United States Of America As Represented By The Department Of Health And Human Services
Screening test for reverse-transcriptase containing virus such as non-A, non-B hepatitis, NANBH
US4673634A
(en)
*
1985-03-08
1987-06-16
The United States Of America As Represented By The Department Of Health And Human Services
Purified antigen from non-A, non-B hepatitis causing factor
JPS62181798A
(en)
*
1986-02-06
1987-08-10
Isao Ono
Monoclonal antibody
EP0261233A4
(en)
*
1986-04-01
1988-08-29
Genelabs Inc
Immortalized virus-specific tissue cells.
JPS6391328A
(en)
*
1986-10-07
1988-04-22
Mitsubishi Kasei Corp
Antigen on hepatitis of non-a and non-b type
FR2606515B1
(en)
*
1986-11-07
1992-02-21
Pasteur Institut
PROCESS FOR ISOLATING A NEW VIRAL AGENT AND THE ANTIGEN ASSOCIATED WITH IT, VIRAL AGENT AND ANTIGEN OBTAINED THEREBY AND METHOD FOR DETECTING THE SAME ANTIGEN USING AN APPROPRIATE IMMUNOLOGICAL REAGENT
US5032511A
(en)
*
1987-03-31
1991-07-16
Mitsubishi Kasei Corporation
DNA fragments coding for antigens specific to non-A non-B hepatitis, expression vectors containing said DNA fragments, transformants and process for producing said antigens
JPH06156196A
(en)
*
1992-11-25
1994-06-03
Mitsuba Electric Mfg Co Ltd
Intermittent time control method of wiper
1989
1989-06-28
WO
PCT/US1989/002817
patent/WO1990000597A1/en
not_active
Application Discontinuation
1989-06-28
EP
EP19890909076
patent/EP0423239A4/en
not_active
Withdrawn
1989-06-28
JP
JP1508518A
patent/JPH04501203A/en
active
Pending
1989-06-28
AU
AU40464/89A
patent/AU4046489A/en
not_active
Abandoned
1989-07-06
CN
CN89104546A
patent/CN1041005A/en
active
Pending
Cited By (2)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
AU623433B2
(en)
*
1988-09-30
1992-05-14
Research Foundation For Microbial Diseases Of Osaka University, The
Non-a, non-b hepatitis virus antigen peptide
AU673135B2
(en)
*
1990-08-25
1996-10-31
New York Blood Center, Inc., The
Non-A, non-B hepatitis virus antigen, diagnostic methods and vaccines
Also Published As
Publication number
Publication date
JPH04501203A
(en)
1992-03-05
EP0423239A4
(en)
1992-05-20
CN1041005A
(en)
1990-04-04
EP0423239A1
(en)
1991-04-24
WO1990000597A1
(en)
1990-01-25
Similar Documents
Publication
Publication Date
Title
AU4046489A
(en)
1990-02-05
Post-transfusion, non-a, non-b hepatitis virus and antigens
US5218099A
(en)
1993-06-08
Post-transfusion, non-A, non-B hepatitis virus polynucleotides
AU642942B2
(en)
1993-11-04
Viral agent
RU2155228C2
(en)
2000-08-27
Genome sequence of hepatitis c virus for diagnostic and therapeutic aims
US5879904A
(en)
1999-03-09
Nucleotide and peptide sequences of a hepatitis C virus isolate, diagnostic and therapeutic applications
JP3746291B2
(en)
2006-02-15
Hepatitis E virus vaccine and inoculation method thereof
CA2111108A1
(en)
1992-12-23
Hepatitis c diagnostics and vaccines
NZ230560A
(en)
1992-05-26
Non-a, non-b (nanbv) hepatitis antigens and their use in blood screening and diagnosis
JP2007031440A
(en)
2007-02-08
Enterically transmitted non-a non-b hepatitis viral factor
KR0178399B1
(en)
1999-04-01
Enterically transmitted non-a/non-b hepatitis viral agent and characteristic epitopes thereof
CA2125700A1
(en)
1993-07-22
Hepatitis e virus peptide antigens and antibodies
US20160244492A1
(en)
2016-08-25
Hcbi sequences as an early marker for the future development of cancer and diseases of the cns and as a target for cancer treatment and prevention
PL191312B1
(en)
2006-04-28
A vaccine-induced hepatitis b viral strain and uses thereof
EP0551275B1
(en)
1994-12-21
Non-a non-b sequences
JPH11500001A
(en)
1999-01-06
Recombinant protein of Pakistan strain of hepatitis E, its diagnostic method and its use in vaccination
US5789559A
(en)
1998-08-04
DNA sequences of enterically transmitted non-A/non-B hepatitis viral agent
AU741656B2
(en)
2001-12-06
Non-B non-C non-G hepatitis virus gene, polynucleotide, polypeptide, virion, method for separating virion, and method for detecting virus
US5824649A
(en)
1998-10-20
DNA sequences of enterically transmitted non-A/non-B hepatitis viral agent and characteristic epitopes thereof
US5866139A
(en)
1999-02-02
Nucleotide and peptide sequences of a hepatitis C virus isolate, diagnostic and therapeutic applications
KR20020065559A
(en)
2002-08-13
Hepatitis virus sentinel virus i (svi)
US20040176583A1
(en)
2004-09-09
Non-B, non-C, non-G hepatitis virus gene, polynucleotide, polypeptide, virus particle, method for isolating virus particle, and method for detecting virus
US20030165540A1
(en)
2003-09-04
Sentinel virus II
WO1998029747A1
(en)
1998-07-09
Reagents and methods for detecting hepatitis gb virus antigen
None